Vorinostat (SAHA, MK0683)

Catalog No.S1047 Synonyms: SAHA, MK0683, suberoylanilide hydroxamic acid

Molecular Weight(MW): 264.3

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

Cited by 182 Publications

Cell, 2019, 176(1-2):198-212

PubMed: 30503211 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cell, 2014, 158(5):989-99

PubMed: 25131989 ( click the link to review the publication )

Nature, 2011, 471(7337):235-9

PubMed: 21390130 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

J Pineal Res, 2019, 66(3):e12556

PubMed: 30648757 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Theranostics, 2019, 9(2):540-553

PubMed: 30809292 ( click the link to review the publication )

Cancer Res, 2019, 79(7):1658-1670

PubMed: 30737231 ( click the link to review the publication )

Cancers (Basel), 2019, 11(4)

PubMed: 30935067 ( click the link to review the publication )

Clin Epigenetics, 2019, 11(1):85

PubMed: 31142371 ( click the link to review the publication )

Front Immunol, 2019, 9:3162

PubMed: 30723480 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Pharmacol Res, 2019, 146:104281

PubMed: 31125601 ( click the link to review the publication )

Apoptosis, 2019, 24(5-6):404-413

PubMed: 30997620 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(5):677-688

PubMed: 30224636 ( click the link to review the publication )

Stem Cells Dev, 2019, 28(7):438-453

PubMed: 30667343 ( click the link to review the publication )

Chem Biol Interact, 2019, 306:54-61

PubMed: 30958996 ( click the link to review the publication )

Exp Hematol, 2019, 72:60-71

PubMed: 30769020 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3579-3584

PubMed: 31262882 ( click the link to review the publication )

Exp Ther Med, 2019, 17(6):4547-4553

PubMed: 31186678 ( click the link to review the publication )
Clin Cancer Res, 2018, 24(16):3941-3954

PubMed: 29764852 ( click the link to review the publication )

J Control Release, 2018, 275:117-128

PubMed: 29474960 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):32

PubMed: 29486795 ( click the link to review the publication )

Cancer Lett, 2018, 432:121-131

PubMed: 29890207 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2767-2779

PubMed: 30232145 ( click the link to review the publication )

Exp Cell Res, 2018, 371(1):231-237

PubMed: 30107147 ( click the link to review the publication )

Oncol Rep, 2018, 39(1):264-270

PubMed: 29115632 ( click the link to review the publication )

Ann Hematol, 2018, 97(5):839-849

PubMed: 29359239 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 498(3):481-486

PubMed: 29505792 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(8):398-407

PubMed: 30484863 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3139-3149

PubMed: 27986747 ( click the link to review the publication )

Haematologica, 2017, 102(4):736-745

PubMed: 27979926 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(2):211-220

PubMed: 28860353 ( click the link to review the publication )

Pharm Res, 2017, 34(3):668-679

PubMed: 28101809 ( click the link to review the publication )

Cancer Med, 2017, 6(11):2673-2685

PubMed: 29024573 ( click the link to review the publication )

Int J Cell Biol, 2017, 2017:6169310

PubMed: 28321257 ( click the link to review the publication )

Connect Tissue Res, 2017, 58(1):64-75

PubMed: 27404795 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:88-95

PubMed: 28323055 ( click the link to review the publication )

Am J Surg, 2017, 213(4):645-651

PubMed: 28007318 ( click the link to review the publication )

CPT Pharmacometrics Syst Pharmacol, 2017, 6(11):756-764

PubMed: 29045072 ( click the link to review the publication )

Sci Rep, 2017, 7(1):2290

PubMed: 28536458 ( click the link to review the publication )

Oncotarget, 2017, 10.18632/oncotarget.15017

PubMed: 28157715 ( click the link to review the publication )

Ann Oncol, 2016, 27(3):508-13

PubMed: 26658891 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )
Cancer Res, 2016, 76(23):7001-7011

PubMed: 27671680 ( click the link to review the publication )

Int J Cancer, 2016, 139(1):194-204

PubMed: 26914605 ( click the link to review the publication )

Drug Discov Today, 2016, 21(9):1553-1560

PubMed: 27371506 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1364-75

PubMed: 27196750 ( click the link to review the publication )

Mol Cell Proteomics, 2016, 15(6):2076-92

PubMed: 27067055 ( click the link to review the publication )

Neuropharmacology, 2016, 107:111-121

PubMed: 26970016 ( click the link to review the publication )

Biochem Pharmacol, 2016, 102:130-140

PubMed: 26718586 ( click the link to review the publication )

Am J Pathol, 2016, 186(10):2701-8

PubMed: 27555113 ( click the link to review the publication )

J Biol Chem, 2016, 291(19):10131-47

PubMed: 27022024 ( click the link to review the publication )

Neurochem Int, 2016, 96:24-31

PubMed: 27103167 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2453-2463

PubMed: 27748897 ( click the link to review the publication )

Anal Bioanal Chem, 2016, 408(13):3547-53

PubMed: 26968571 ( click the link to review the publication )

BMC Cancer, 2016, 16:667

PubMed: 27549189 ( click the link to review the publication )

J Hum Genet, 2016, 10.1038/jhg.2016.61

PubMed: 27251006 ( click the link to review the publication )

J Hum Genet, 2016, 10.1038/jhg.2016.61

PubMed: 27251006 ( click the link to review the publication )

Inflammation, 2016, 39(1):39-46

PubMed: 26228975 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0145985

PubMed: 26726879 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:6843-6855

PubMed: 27877053 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(3):692-9

PubMed: 26084206 ( click the link to review the publication )

Genet Mol Res, 2016, 15(4)

PubMed: 27819724 ( click the link to review the publication )

Oncotarget, 2016, 7(36):58142-58147

PubMed: 27494885 ( click the link to review the publication )

Sci Rep, 2016, 6:21678

PubMed: 26902929 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404580

PubMed: 25759362 ( click the link to review the publication )
Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2701

PubMed: 25813020 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

Int J Cancer, 2015, 136(11):2717-29

PubMed: ( click the link to review the publication )

Cancer Lett, 2015, 356(2 Pt B):828-36

PubMed: 25449774 ( click the link to review the publication )

Cancer Lett, 2015, 366(1):32-43

PubMed: 26028172 ( click the link to review the publication )

Breast Cancer Res, 2015, 17:33

PubMed: 25888415 ( click the link to review the publication )

Acta Neuropathol Commun, 2015, 3(1):22

PubMed: 25853389 ( click the link to review the publication )

Endocr Relat Cancer, 2015, 22(5):777-92

PubMed: 26206775 ( click the link to review the publication )

Br J Haematol, 2015, 168(3):371-83

PubMed: ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(4):1337-52

PubMed: 26101701 ( click the link to review the publication )

Neuropharmacology, 2015, 99:67-78

PubMed: 26188143 ( click the link to review the publication )

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed: ( click the link to review the publication )

Biochem Pharmacol, 2015, 94(2):79-90

PubMed: 25600908 ( click the link to review the publication )

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed: ( click the link to review the publication )

Apoptosis, 2015, 20(7):975-85

PubMed: 25835755 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: 25540204 ( click the link to review the publication )

J Biol Chem, 2015, 290(3):1829-36

PubMed: 25492871 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: ( click the link to review the publication )

BMC Cancer, 2015, 15(1):273

PubMed: 25880212 ( click the link to review the publication )

FEBS Lett, 2015, 589(10):1080-8

PubMed: 25816750 ( click the link to review the publication )

J Biotechnol, 2015, 10.1016/j.jbiotec.2015.02.029

PubMed: 25746901 ( click the link to review the publication )

Mol Med Rep, 2015, 12(3):4291-4297

PubMed: 26095064 ( click the link to review the publication )

Sci Transl Med, 2014, 6(256):256ra135

PubMed: 25273096 ( click the link to review the publication )
Nat Commun, 2014, 5:3361

PubMed: 24553445 ( click the link to review the publication )

Clin Cancer Res, 2014, 10.1158/1078-0432.CCR-14-0384

PubMed: 25355930 ( click the link to review the publication )

Int J Cancer, 2014, 135(7):1721-32

PubMed: 24615207 ( click the link to review the publication )

Diabetes, 2014, 63(9):2924-34

PubMed: 24722245 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.10.034

PubMed: ( click the link to review the publication )

Cancer Lett, 2014, 351(1):50-8

PubMed: 24814395 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1177

PubMed: 24743732 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(12):2784-92

PubMed: 25319394 ( click the link to review the publication )

J Mol Biol, 2014, 426(20):3442-53

PubMed: 24657767 ( click the link to review the publication )

Hum Gene Ther, 2014, 25(7):599-608

PubMed: 24568341 ( click the link to review the publication )

J Biol Chem, 2014, 289(14):9918-25

PubMed: 24515107 ( click the link to review the publication )

Cancer Cell Int, 2014, 10.1186/s12935-014-0112-x

PubMed: ( click the link to review the publication )

Mol Cell Biol, 2014, 34(7):1280-9

PubMed: 24469401 ( click the link to review the publication )

Proteomics Clin Appl, 2014, 8(11-12):924-31

PubMed: 25091122 ( click the link to review the publication )

J Alzheimers Dis, 2014, 41(4):1193-205

PubMed: 24844691 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(5):578-85

PubMed: 24556916 ( click the link to review the publication )

BMC Cancer, 2014, 14(1):373

PubMed: 24886166 ( click the link to review the publication )

FEBS Lett, 2014, 588(9):1571-9

PubMed: 24607544 ( click the link to review the publication )

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Pharmacol Res Perspect, 2014, 2(3):e00043

PubMed: 25505589 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )
Cytometry A, 2014, 85(1):78-87

PubMed: 24038859 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Pharmacology Research Perspectives, 2014, 10.1002/prp2.43

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(15):5965-77

PubMed: 25115389 ( click the link to review the publication )

Blood, 2013, 123(5):706-16

PubMed: 24319254 ( click the link to review the publication )

Nat Struct Mol Biol, 2013, 20(3):317-25

PubMed: 23377543 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 111(3):E364-73

PubMed: 24395801 ( click the link to review the publication )

PLoS Biol, 2013, 12(1):e1001758

PubMed: 24409098 ( click the link to review the publication )

Cancer Res, 2013, 73(8):2428-34

PubMed: 23382048 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Int J Cancer, 2013, 132(9):2200-8

PubMed: 23024001 ( click the link to review the publication )

Neuropsychopharmacology, 2013, 38(9):1674-84

PubMed: 23474591 ( click the link to review the publication )

Oncogene, 2013, 33(33):4265-72

PubMed: 24292675 ( click the link to review the publication )

Oncogene, 2013, 32(10):1316-29

PubMed: 22543582 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e733

PubMed: 23868066 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Br J Haematol, 2013, 160(2):188-98

PubMed: 23167276 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Biol Chem, 2013, 288(35):25593-602

PubMed: 23878197 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14400-7

PubMed: 23539624 ( click the link to review the publication )

Mol Carcinog, 2013, 52(3):218-28

PubMed: 22121107 ( click the link to review the publication )

Front Pharmacol, 2013, 4:44

PubMed: 23596417 ( click the link to review the publication )

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462 ( click the link to review the publication )

Cell Cycle, 2013, 12(13):2073-83

PubMed: 23759592 ( click the link to review the publication )
PLoS One, 2013, 8(1):e53766

PubMed: 23320102 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

J Exp Med, 2012, 209(1):35-50

PubMed: 22231305 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(14):3822-33

PubMed: 22623731 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(2):408-16

PubMed: 22038994 ( click the link to review the publication )

Cancer Res, 2012, 72(9):2251-61

PubMed: 22422937 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):2029-39

PubMed: 22858545 ( click the link to review the publication )

Cell Death Differ, 2012, 19(8):1317-27

PubMed: 22322857 ( click the link to review the publication )

Eur J Cancer, 2012, 48(7):1096-107

PubMed: 22154545 ( click the link to review the publication )

Diabetologia, 2012, 55(9):2421-31

PubMed: 22772764 ( click the link to review the publication )

FASEB J, 2012, 26(7):3032-41

PubMed: 22459148 ( click the link to review the publication )

J Neurochem, 2012, 123 Suppl 2:108-15

PubMed: 23050648 ( click the link to review the publication )

J Leukoc Biol, 2012, 91(5):701-9

PubMed: 22028329 ( click the link to review the publication )

J Biol Chem, 2012, 287(43):36609

PubMed: 22952229 ( click the link to review the publication )

Mol Carcinog, 2012, 52(6):459-74

PubMed: 22308110 ( click the link to review the publication )

Invest New Drugs, 2012, 30(2):541-7

PubMed: 21107885 ( click the link to review the publication )

Pharm Res, 2012, 29(7):1960-76

PubMed: 22415140 ( click the link to review the publication )

Oncol Rep, 2012, 28(1):105-10

PubMed: 22484732 ( click the link to review the publication )

PLoS One, 2012, 7(9):e44265

PubMed: 22957056 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52335

PubMed: 23272238 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52753

PubMed: 23300762 ( click the link to review the publication )

Chronobiol Int, 2012, 29(8):982-93

PubMed: 22891617 ( click the link to review the publication )

Biochem Biophys Res Co, 2012, 420(2):325-30

PubMed: 22425986 ( click the link to review the publication )

Pediatr Surg Int, 2012, 28(6):579-89

PubMed: 22526548 ( click the link to review the publication )
Protein Expr Purif, 2012, 86(1):45-52

PubMed: 21992606 ( click the link to review the publication )

Brain, 2011, 134(Pt 8):2408-21

PubMed: 21772061 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(9):2819-29

PubMed: 21357681 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(16):5311-21

PubMed: 21724551 ( click the link to review the publication )

Genes Dev, 2011, 25(24):2610-8

PubMed: 22016339 ( click the link to review the publication )

J Neurosci, 2011, 31(11):3990-9

PubMed: 21411642 ( click the link to review the publication )

J Transl Med, 2011, 9:37

PubMed: 21477288 ( click the link to review the publication )

Retrovirology, 2011, 2(3):411-23

PubMed: 21966324 ( click the link to review the publication )

Mol Med, 2011, 17(5-6):466-72

PubMed: 21424110 ( click the link to review the publication )

PLoS One, 2011, 6(7):e22739

PubMed: 21818379 ( click the link to review the publication )

BMC Neurosci, 2011, 12:50

PubMed: 21615950 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

J Pharmacol Exp Ther, 2010, 86(16):8765-72

PubMed: 20739454 ( click the link to review the publication )

Exp Dermatol, 2010, 19(12):1096-102

PubMed: 20629733 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

Targets

HDAC ^[1]
(Cell-free assay)

~10 nM

In vitro

Vorinostat inhibits the activities of HDAC1 and HDAC3 with IC50 of 10 nM and 20 nM, respectively. Vorinostat also results in a marked hyperacetylation of histone H4. ^[1] Vorinostat inhibits the growth of three prostate cancer cell lines LNCaP, PC-3 and TSU-Pr1 at micromolar concentrations (2.5-7.5 μM), and induces dose-dependent cell death in LNCaP cells. ^[2] Vorinostat treatment in MCF-7 cells inhibits cell proliferation at an IC50 of 0.75 μM resulting in the accumulation of cells in the G1 and G2-M phase of the cell cycle. Vorinostat also induces differentiation in the estrogen receptor-negative cell line SKBr-3 and the retinoblastoma-negative cell line MDA-468. ^[3] Vorinostat treatment at 1 μM for 8 hours or more is sufficient to irreversibly induce apoptosis of human multiple myeloma (MM) cells. The gene expression profiles of Vorinostat treated MM cells are not hallmarked by global transcriptional activation, but by coordinated transcriptional changes of specific functional groups of genes such as cytokine-induced proliferative/survival signaling cascades, oncogenes-tumor suppressor genes, regulators of apoptosis, DNA synthesis-repair and cell cycle, and proteasome-ubiquitin function. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A20	M{DBOmtqdmG\|ZTDBd5NigQ>?		M3LsVlEhcA>?	MWDEUXNQ	NITWWJNidnSrLVjERWMyKGGldHn2bZR6KHerdHigTWM2OCCxZjCwMlEyOiEQvF2=	M{\qdVEyQTZyNEi5
Friend leukemic cell	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrrSpBlPTBizszN	NYLxe\|VnPzJiaB?=	NGe5OZNFVVOR	MXPJR\|UxRTBwOUmg{txO	NUPESY1uOTJzMEm5NVM>
K562	NGjTWo9McW6jc3WgRZN{[Xl?		NIm1eJo3KGh?	NVnYUHpjTE2VTx?=	M1nZWGlvcGmkaYTpc44hd2ZiaIXtZY4hcGm\|dH;u[UBl\WGlZYT5cIF{\SBqbXn4eJVz\SCxZjDISGFEOSCjbnSgTGRCSzJrIIfpeIghUUN3MDDv[kAxNjBzIN88US=>	M1\hZ\|EzPDF7M{iw
HT1080	MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoH6O\|IhcA>?	M1XrdGROW09?	NF7kcG5KSzVyPUKuOEDPxE1?	M{jOSlEzOjdyMUe1
H1299	MV7LbY5ie2ViQYPzZZk>		M3HiXFIxKG2rbh?=	MoTKSG1UVw>?	NEK5cmpKdmirYnn0c5J6KGGldHn2bZR6KGGpYXnud5QhUESDQzDlcpp6dWVid3n0bEBKSzVyIH;mJFAvOTl2IN88US=>	MVWxOFUzOTR{Mh?=
H1299	M{TnXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWrZPJlMPzJiaB?=	NYXBUo5pTE2VTx?=	MX;JR\|UxRTdwMkSg{txO	NF62UmQyPDV{MUSyNi=>
HeLa	MYfLbY5ie2ViQYPzZZk>		NULySIN7OzBibXnu		MmXSTY5pcWKrdH;yfUBkd26lZX70doF1cW:wIHHnZYlve3RiaHnzeI9v\SCmZXHj[ZR6dGG\|ZTD3bZRpKEmFNUCgc4YhOC5{ODFOwG0>	NYDqcmlyOTV4MEO5OFk>
LOX-IMVI	MnrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1HwW\|Q5KGh?		NIrzfIZKSzVyPUGuN{DPxE1?	MVixOVcyPTR5MB?=
NCI-H226	M{e5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVfoT2RiPDhiaB?=		Mk\NTWM2OD1{Lk[g{txO	NHLPWVMyPTdzNUS3NC=>
RXF-631L	NXu1eHFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnT1OFghcA>?		NFvmN4lKSzVyPUKg{txO	NUe5V2t6OTV5MUW0O\|A>
SNB-78	M2OwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoL5OFghcA>?		MXfJR\|UxRTF4IN88US=>	MUixOVcyPTR5MB?=
St-4	NInLWIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYe0PEBp		NWLWPGs{UUN3ME21MlIh\|ryP	MVqxOVcyPTR5MB?=
ARP1	M2rORmZ2dmO2aX;uJGF{e2G7	MWWyJO69VQ>?	NF3MSHQ3KGh?		NITwTFFKdmS3Y4Tpc44hd2ZiUEKxW2FHOSCpZX7lJIV5eHKnc4Ppc44>	MoXDNVQ4OzR6ME[=
CEM	MYnLbY5ie2ViQYPzZZk>		NEH0fGwyKGh?	M3vTbWROW09?	M1rUfGlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD6zN{DPxE1?	MYexOlQzODB4NB?=
HCT15	MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmSyOFghcA>?		M1fqfmdKPTB;MD64NkDPxE1?	M2jofVE3PzJ\|MkK3
NCI-H23	NYPzTGdCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFKyWJo1QCCq		NGjvPZpIUTVyPUCuPVIh\|ryP	NI\2VXcyPjd{M{KyOy=>
GM15850	NHvhc\|VMcW6jc3WgRZN{[Xl?	NGPyWoMzNjVizszN	MV[5OkBp	MYPEUXNQ	MlXUTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSEOgcJl{cW6nIEG0JIFk\XS7bHH0bY9vKG:oIF\YUkBo\W6n	MUGxOlkzOTN4Nx?=
GM15850	NEDWdZZMcW6jc3WgRZN{[Xl?	NETZPG4zNjVizszN	MUW5OkBp	M3vIUWROW09?	MorZTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSESgcJl{cW6nIEWgZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV?	NED0OHYyPjl{MUO2Oy=>
GM15850	MkmwT4lv[XOnIFHzd4F6	NUjrUmtpOi53IN88US=>	NUG5XYlYQTZiaB?=	M1ryW2ROW09?	NYDr[lNoUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFEzKGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	M3WzNFE3QTJzM{[3
GM15850	MX3LbY5ie2ViQYPzZZk>	M4HkTFIvPSEQvF2=	MXG5OkBp	NGPUPWRFVVOR	NFfhPJdKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIN{BtgXOrbnWgPUBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?=	NI\yN2UyPjl{MUO2Oy=>
GM15850	MnTKT4lv[XOnIFHzd4F6	NFm0b2UzNjVizszN	M3HTVVk3KGh?	NXrXTlZVTE2VTx?=	M4r5OWlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIFi0JIx6e2mwZTC4JIFk\XS7bHH0bY9vKG:oIF\YUkBo\W6n	NFXGXlIyPjl{MUO2Oy=>
GM15850	NUTpfIhUU2mwYYPlJGF{e2G7	MWKyMlUh\|ryP	NEXhNVc6PiCq	M4LRbmROW09?	NUPGWZZxUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFE3KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	MVyxOlkzOTN4Nx?=
U937	MV;GeY5kfGmxbjDBd5NigQ>?	NYfVdIZ4PSEQvF2=	MorkNlQhcA>?	NHnGNHNFVVOR	M1rZTmNmdGxiY4njcIUh[XK{ZYP0JIJ6KGGlY4XteYxifGmxbjDheEBUN0d{L12gdIhie2V?	MYixO\|AxPDdzOB?=
H661	M{D5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{GzTVQ5KGh?		MnXUTWM2OD1zIN88US=>	NUPOOmxFOTdzNUewNFk>
U937	Mmf2SpVv[3Srb36gRZN{[Xl?	NXzB[pdvPSEQvF2=	M{CzSlI1KGh?	M1y5fWROW09?	M{LacGlv[3KnYYPlJIlvKGirc4TvcoUhUDNiYXPleJlt[XSrb36=	MnLnNVc1PDd5NUC=
U937	NX:0bWtwTnWwY4Tpc44hSXO\|YYm=	MlnYNUDPxE1?	M1LyR\|I1KGh?	NES2TXBFVVOR	M1y0bWVn\mWldDDvckBidHCqYTD0eYJ2dGmwIHHj[ZR6dGG2aX;u	MnvQNVc1PDd5NUC=
RAW264.7	NF;6O4lHfW6ldHnvckBCe3OjeR?=	NI\YcFQyOCEQvF2=	MnzlNlRp	NWf2dlBmf2G2ZYK=	M1jiZ2lvcGmkaYTpc44hd2ZiTGDTMZN1cW23bHH0[YQhXE6IYXzwbIEheHKxZIXjeIlwdiC5aYToJGlEPTBib3[gNE44PiEQvF2=	MXmxO\|Q4PzVzOB?=
RAW264.7	Mo[xSpVv[3Srb36gRZN{[Xl?	NIDYPYMyOCEQvF2=	MoDDNlRp	MXj3ZZRmeg>?	MnXlTY5pcWKrdHnvckBw\iCOUGOtd5RqdXWuYYTl[EBPVyCycn;keYN1cW:wIIfpeIghUUN3MDDv[kAyNjh6IN88US=>	MkTyNVc1Pzd3MUi=
SC9	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYm0PEBp		M{jVZ2lEPTB;MD62NFYh\|ryP	MmW2NVc2ODd{MUm=
ST14A	MWLGeY5kfGmxbjDBd5NigQ>?	NGnQdnU2KG6P	MnS1O\|IhcA>?		NXP0PWduUW6lcnXhd4UhcW5iUlXTWE9PWlOIIH3SUmEh\XiycnXzd4lwdg>?	MUCxO\|U3PTl7Mx?=
ST14A	M{PjN2Z2dmO2aX;uJGF{e2G7	MmjTOUBvVQ>?	NFLPc3Q4OiCq		MlXVTY5kemWjc3WgbY4hTTKIMTDtVm5CKGW6cILld5Nqd25?	NFzvPGIyPzV4NUm5Ny=>
PANC1	NFH4eGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV:yb3lqOSEQvF2=			M1nQXWlEPTB;MD60OUDPxE1?	MWSxO\|U5QDd2NB?=
PANC1	NFHwcHBHfW6ldHnvckBCe3OjeR?=	NFPvOVQyKM7:TR?=	MomzNlQhcA>?		M3nRbWlv[3KnYYPlJIlvKHB{MWfBSlEwS0mSMTDn[Y5mKGW6cILld5Nqd25?	NEe2U4kyPzV6OEe0OC=>
PANC1	NFfafIhHfW6ldHnvckBCe3OjeR?=	NHPzTIEyKM7:TR?=	MkXmNlQhcA>?		NVPKVIFnUW6lcnXhd4UhcW5icEK3b4lxOSCpZX7lJIV5eHKnc4Ppc44>	MWexO\|U5QDd2NB?=
PT45	Mn3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTBdYxKSzVyPUSg{txO	MW[xO\|U5QDd2NB?=
ACHN	NX3JUpdvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVnBemlvOjFiaB?=		NELaZVRIUTVyPUCuOlUh\|ryP	MofoNVc3PjJ4ME[=
PC3	NFe1VpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWTqWZU3OjFiaB?=		NIjNZZBIUTVyPUCuO\|Eh\|ryP	M3vFTlE4PjZ{NkC2
A431	NInyNnBEgXSxdH;4bYMhSXO\|YYm=		M3X4VVczKGh?		NX35c4tGUUN3ME20MlIh\|ryP	NIPSPWQyPzZ7MUe2Ny=>
Cal27	M1m3e2N6fG:2b4jpZ{BCe3OjeR?=		NXnGUY5RPzJiaB?=		NEDud\|dKSzVyPUOuNkDPxE1?	MUWxO\|Y6OTd4Mx?=
CCRF-CEM	M1y3Z2N6fG:2b4jpZ{BCe3OjeR?=		MUi3NkBp		NUS3cnFsUUN3ME2wMlgh\|ryP	NF;ySpoyPzZ7MUe2Ny=>
EOL1	NGPLeHREgXSxdH;4bYMhSXO\|YYm=		M4C2[lczKGh?		NYLqXVZ1UUN3ME2xJO69VQ>?	NVXCdnVsOTd4OUG3OlM>
Hec-1-A	NGPXcldEgXSxdH;4bYMhSXO\|YYm=		MlfXO\|IhcA>?		NV6w[3RYUUN3ME2xJO69VQ>?	NEnve5gyPzZ7MUe2Ny=>
HeLa	MVfLbY5ie2ViQYPzZZk>	Mlf6NVAh\|ryP	M4G3NlMxKG2rbh?=	MoTBSG1UVw>?	NHyxfG5KdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGhFSUNzIIfpeIghUUN3MDDv[kAxNjB{IN88US=>	MY[xO\|Y6OTd4Mx?=
RKOp21	M1rPUmN6fG:2b4jpZ{BCe3OjeR?=		NX7rVIFSPzJiaB?=		NXXyNlc5UUN3ME2xMlc3KM7:TR?=	NV25eIdJOTd4OUG3OlM>
Saos2	NUjrPYNOS3m2b4TvfIlkKEG\|c3H5		NHP5cmY4OiCq		M1f1O2lEPTB;Mj6zJO69VQ>?	MlXrNVc3QTF5NkO=
SK-OV-3	M1PKdGN6fG:2b4jpZ{BCe3OjeR?=		NEL3R2E4OiCq		MUHJR\|UxRTJwMjFOwG0>	M3vWdVE4PjlzN{[z
U87MG	NGDYOoREgXSxdH;4bYMhSXO\|YYm=		NWnmcXA2PzJiaB?=		NHXhelZKSzVyPUGxJO69VQ>?	MWWxO\|Y6OTd4Mx?=
NUGC3	NIXwToVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIGxVXI2KM7:TR?=	Ml\NNlQhcA>?		MUXHTVUxRTJwN{mg{txO	MlrnNVc6ODR6NEO=
CCD1059SK	M1:wdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXVZoZKSzVyPUSzMlUh\|ryP	MUSxPFI1PzV3NB?=
HepG2	NV7OTpdPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXhTWM2OD1yLkCwNFYh\|ryP	MmPmNVgzPDd3NUS=
HT1080	NISxT3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTBwMECyOEDPxE1?	M2HzVVE5OjR5NUW0
SKBR3	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{PzZmlEPTB;MD64JO69VQ>?	MVexPFI1PzV3NB?=
SNB78	NGr2V4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml\iSWM2OD1zNjFOwG0>	M3rlflE5OjR5NUW0
SQ20B	M2G5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1;OemlEPTB;MzFOwG0>	NWj4fJZNOTh{NEe1OVQ>
St4	M{LtZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\FR\|UxRTVwMjFOwG0>	NUTsS4VkOTh{NEe1OVQ>
MCF7	NFfKNIpHfW6ldHnvckBCe3OjeR?=	Mli0NVAh\|ryP	M3nIWlghcA>?	MVrEUXNQ	NGrSS3ZKdmS3Y4Tpc44hd2ZidIXieYxqdiCqeYDldoFk\XS7bHH0bY9v	NV7TS2JSOTh{NkmyNlY>
HEK293	NHjlSJNMcW6jc3WgRZN{[Xl?		NH64OGIyKGh?	Mln4SG1UVw>?	NFToXHVKdmirYnn0bY9vKG:oIFjERWMyKHerdHigTWM2OCCxZjCwMlA{KM7:TR?=	NXzBT5R3OTh\|MEi1OlM>
HEK293	MVXLbY5ie2ViQYPzZZk>		MVWxJIg>	M{P1R2ROW09?	NXq0OW9NUW6qaXLpeIlwdiCxZjDISGFEOyC5aYToJGlEPTBib3[gNE4xPTdizszN	MU[xPFMxQDV4Mx?=
G401	NULVcIRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEPoXI04OiCq	MYHEUXNQ	NXPCcJQ1UUN3ME2xJO69VQ>?	MUixPFM4ODN5Mx?=
HeLa	NGfEemFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M37OXVczKGh?	MUHEUXNQ	MVLJR\|UxRTBwNE[g{txO	MlTwNVg{PzB\|N{O=
Human renal epithelial cell	NWjHOZE6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWW3NkBp	NF;5O25FVVOR	M4L5cWlEPTB;MUSg{txO	MVKxPFM4ODN5Mx?=
U937	M4fYZ2Z2dmO2aX;uJGF{e2G7	M2HHbVUh\|ryP	MWKyOEBp		NGqxU5pKdmS3Y4Tpc44hd2ZiaHnzeI9v\SCKNDDofZBmemGlZYT5cIF1cW:w	MXGxPFM5OTJ\|OB?=
U937	NUH6U2lxTnWwY4Tpc44hSXO\|YYm=	NInXXWc2KM7:TR?=	MWSyOEBp		NHLBN3BKdmS3Y4Tpc44hd2ZiYXzwbIEhfHWkdXzpckBpgXCncnHj[ZR6dGG2aX;u	NEnOOFgyQDN6MUKzPC=>
U937	Ml[2SpVv[3Srb36gRZN{[Xl?	MWK1JO69VQ>?	M4LSPFI1KGh?		MmPuTY5lfWO2aX;uJI9nKHB{MTDlfJBz\XO\|aX;u	MV6xPFM5OTJ\|OB?=
U937	MkSzSpVv[3Srb36gRZN{[Xl?	M1LrNlUh\|ryP	NE\XS48zPCCq		NU\nV2pYUW6mdXP0bY9vKG:oIHHwc5B1d3Orcx?=	NFS2V2UyQDN6MUKzPC=>
U937	NGnCToVHfW6ldHnvckBCe3OjeR?=	NUjYSIpPPSEQvF2=	NXTPem9KOjRiaB?=		M{\5Umlv\HWldHnvckBw\iCpcnHueYxw[3m2aXOg[Iln\mW{ZX70bYF1cW:w	MYixPFM5OTJ\|OB?=
U937	NXzV[3BRU2mwYYPlJGF{e2G7	NWTWe2RJPSEQvF2=	M3e2bFI1KGh?		NYHHelhqUW6qaXLpeIlwdiCxZjDoeY1idiCKRFHDNS=>	MnX5NVg{QDF{M{i=
U937	M{DT[2tqdmG\|ZTDBd5NigQ>?	NX;TbldDPSEQvF2=	Ml7VNlQhcA>?		M{fXT2lvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{S=	MlvTNVg{QDF{M{i=
HEK-TE	M3fId2Z2dmO2aX;uJGF{e2G7	M{i3XFUh\|ryP	NF[yWWQ3cA>?	Mor3SG1UVw>?	NIfmfpBKdmO{ZXHz[UBqdiCqaYP0c45mKEh\|IHHj[ZR6dGG2aX;u	MXexPFQ{PDF2NB?=
HPDE6c7	NEnKNm5EgXSxdH;4bYMhSXO\|YYm=	NIfqcW82OCEQvF2=	MYm3NkBp	NGjnZmJFVVOR	NX7hcm1HUUN3ME2xMlMh\|ryP	NGTsWpMyQDR7NES2Ny=>
Human microvascular epithelial cell	M2fldWN6fG:2b4jpZ{BCe3OjeR?=	NILoS5M2OCEQvF2=	MmH1O\|IhcA>?	MlOwSG1UVw>?	M4HWSWlEPTB;MT6zJO69VQ>?	MkDMNVg1QTR2NkO=
Hup T3	M3\MS2N6fG:2b4jpZ{BCe3OjeR?=	MVG1NEDPxE1?	MV23Nog>	MnTzSG1UVw>?	M1jke2lEPTB;MD64JO69VQ>?	NUm5S5hLOTh2OUS0OlM>
Mia Paca2	M4PQW2N6fG:2b4jpZ{BCe3OjeR?=	M3rDZlUxKM7:TR?=	NGXGUZo4Omh?	NFXINlBFVVOR	MYTJR\|UxRTFwMTFOwG0>	M4fpVVE5PDl2NE[z
Panc 04.03	NHTRZ2hEgXSxdH;4bYMhSXO\|YYm=	MmrROVAh\|ryP	NELiZ5c4Omh?	NXXyWmlwTE2VTx?=	NGPTW4VKSzVyPUGuNkDPxE1?	MXexPFQ6PDR4Mx?=
SU 86.86	NV3D[po2S3m2b4TvfIlkKEG\|c3H5	M2DvdlUxKM7:TR?=	NX:2UWZzPzKq	M1vjNWROW09?	MW\JR\|UxRTFwMzFOwG0>	M4DsOFE5PDl2NE[z
HEK293	M4LKN2tqdmG\|ZTDBd5NigQ>?		NUHyRnprOyCq		NUDqW5R{UW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBJTEGFNjDlfJBz\XO\|aX;uJJdqfGhiSVO1NEBw\iByLkCxPUDPxE1?	NFexWnUyQDV3OE[2PS=>
HeLa	M3KwbmtqdmG\|ZTDBd5NigQ>?		MV2yJIg>		MXvJcohq[mm2aX;uJI9nKG63Y3zlZZIhUESDQzD3bZRpKEmFNUCgc4YhOC5yOEOg{txO	MX6xPFU2QDZ4OR?=
RAW264.7	NGTMO2JHfW6ldHnvckBCe3OjeR?=	MWSyJO69VQ>?	MVqzMlUhcA>?	M1zTXGROW09?	M13TXGFvfGmvYXzhdolidCCjY4Tpeol1gSCjZ3HpcpN1KFCuYYPtc4RqfW1iZnHsZ4lx[XK3bTDpcoZm[3SnZDD3bZRpKEmFNUCgc4YhOC5zMTFOwG0>	M3y3VVE5PjR2OU[5
NB4			M{TXPVQ5cA>?	M{LRXWROW09?	MWTJR\|UxRTBwNjFOwG0>	NULuPVMzOTh5MkOzOFk>
HEK293	MWnGeY5kfGmxbjDBd5NigQ>?	MoHpNVAh\|ryP	M2ri[\|I1KGh?	MonvSG1UVw>?	MUjBZ5RqfmG2aX;uJI9nKG2xdYPlJHdvfDOjIIPp[45idGmwZzDlfJBz\XO\|ZXS=	MkHLNVkxOjJ4N{W=
HCT116	NFTYW5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWe3Nog>	MVjEUXNQ	NIrBfppKSzVyPUCuN\|Eh\|ryP	M4C5VFE6ODh2Mkm0
HeLa	NI\Ke2dMcW6jc3WgRZN{[Xl?	NGnXcFUzKM7:TR?=	M1LQTVMxKG2rbh?=	NXnWUmp1TE2VTx?=	M{LUUmlvcGmkaYTpc44hd2ZiSFTBR\|IhcW5iaIXtZY4hUGWOYTDj[YxteyC5aYToJGlEPTBib3[gNE4yKM7:TR?=	MljWNVkxQDR{OUS=
IGROV1	NH;ucVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUO3NkBp	M13VO2ROW09?	NWjTPXprUUN3ME2yMlIh\|ryP	MlnvNVkxQDR{OUS=
IGROV1	NXLxVoc1U2mwYYPlJGF{e2G7	MX:1JO69VQ>?	NUXrZoZ5OjRiaB?=	MWnEUXNQ	NX;oSmRZUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IIC1N{Bi[2W2eXzheIlwdg>?	NH20c\|YyQTB6NEK5OC=>
IGROV1	M1i5eWtqdmG\|ZTDBd5NigQ>?	MXKxNEDPxE1?	NXf4NWs3PCCq	MWDEUXNQ	NFrDNmJKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaHnzeI9v\S2KNDDhZ4V1gWyjdHnvci=>	NYTEZ4FROTlyOESyPVQ>
IGROV1	Ml[3T4lv[XOnIFHzd4F6	MWSxNEDPxE1?	NFvaUYQ1KGh?	NV65elhWTE2VTx?=	Mkf5TY5pcWKrdHnvckBw\iCKRFHDOkBie3Onc4Pl[EBieyCjbIDoZU11fWK3bHnuJIFk\XS7bHH0bY9v	NXW0RW9QOTlyOESyPVQ>
T24	MV\LbY5ie2ViQYPzZZk>		M3vDWlMhcA>?		NEnF[JpKdmS3Y4Tpc44hd2ZiaHnzeI9v\SCKMzDhZ4V1gWyjdHnvckB4cXSqIFXDOVAhd2ZiMD6xNkDPxE1?	NVfUWGJHOTlyOESzPVU>
T24	NF36[GtMcW6jc3WgRZN{[Xl?		NYPTUVh{OyCq		NF7LUYJKdmS3Y4Tpc44hd2ZiYXzwbIEhfHWkdXzpckBi[2W2eXzheIlwdiC5aYToJGVEPTBib3[gNE4zPSEQvF2=	NGj1d4kyQTB6NEO5OS=>
HeLa	MVzLbY5ie2ViQYPzZZk>		NX3QTHZ[OTVibXnu	MXLEUXNQ	MVnJcohq[mm2aX;uJI9nKEiGQVO2JIZzd21iboXjcIVieiCneITyZYN1KHerdHigTWM2OCCxZjCwMlA5PTVizszN	NEfHSpEyQTB7M{i4OC=>
HeLa	M1G0W2tqdmG\|ZTDBd5NigQ>?		MWexOUBucW5?	M3P1UmROW09?	MkjHTY5pcWKrdHnvckBw\iCKRFHDPEBnem:vIH71Z4xm[XJiZYj0doFkfCC5aYToJGlEPTBib3[gNU45PiEQvF2=	M4e2SVE6ODl\|OEi0
NCI-H69	M{T3TGN6fG:2b4jpZ{BCe3OjeR?=		NVvrV5RXPzJiaB?=	M4fl[WROW09?	NXHRPWZYUUN3ME2yMlA3KM7:TR?=	MnT3NVkxQTN6OES=
SKMES1	M3\WO2N6fG:2b4jpZ{BCe3OjeR?=		NYLaRpU6PzJiaB?=	NWLN[mczTE2VTx?=	NFjVc3pKSzVyPUKuOFIh\|ryP	NFu2fZcyQTB7M{i4OC=>
S2	MVfLbY5ie2ViQYPzZZk>	MmHvNE4yNTFyIN88US=>	MVyxJIg>		M3ywUGlvcGmkaYTpc44hd2ZiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJGhFSUNzIHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOC5yNUmg{txO	MUCxPVMyPzR3MB?=
SHSY5Y	MWXLbY5ie2ViQYPzZZk>	M4m3OlExKM7:TR?=	M1P0[\|Q5KGh?	M4jtdGROW09?	M3XHemlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD61JO69VQ>?	NGf5bVYyQTN2NEG3OS=>
SHSY5Y	NF;lTnFEgXSxdH;4bYMhSXO\|YYm=	NYH4OHpxOTBizszN	NWradYJvPDhiaB?=	M3W2O2ROW09?	MkHGTWM2OD1{IN88US=>	MoHuNVk{PDRzN{W=
DMS114	NWTqSoM4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NETRcpA1QCCq		NVricpZnT0l3ME2yMlkh\|ryP	NWHnVHZSOTl2MUmyNFU>
HBC5	NH\vSlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUS0PEBp		NVG0RlR6T0l3ME2xO{DPxE1?	NXLkZWh[OTl2MUmyNFU>
SNB78	MlzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mmf0OFghcA>?		Mm\DS2k2OD1zNjFOwG0>	MojZNVk1OTl{MEW=
HeLa	Ml;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M33YW\|czKGh?	Ml\ySG1UVw>?	NGDZT5lKSzVyPUCuOFYh\|ryP	NXXqeHE5OTl2NEG4OFY>
BHK	MnnBT4lv[XOnIFHzd4F6	M2HkOlUh\|ryP	NFT4bIEzPCCq	NWrGOpp1TE2VTx?=	M{\iemlvcGmkaYTpc44hd2ZiSFTBR\|ch\XiycnXzd4VlKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJBt[XOvYTDt[Y1jemGwZTDG[IVtfGF3MEigR2ZVWiCycn;0[Ylv	Mk\aNVk6PjZ5OEm=
CFBE41o-	Ml7GT4lv[XOnIFHzd4F6	NIq5cHc2KM7:TR?=	MUW4JIg>	NH32[IhFVVOR	Ml;qTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGi7cHXyZYNmfHmuYYTpc44hd2ZiaHnzeI9v\SCKMx?=	NIr2Wm0yQTl4Nke4PS=>
CFBE41o-	NX7mdVBzU2mwYYPlJGF{e2G7	NV[5Z3VpPSEQvF2=	NIXZWIg1KGh?	NG[5PWhFVVOR	NV3ObWdXUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJI12fGGwdDDG[IVtfGF3MEigR2ZVWiCycn;0[YlvKGyndnXs	M3[1cFE6QTZ4N{i5
CFBE41o-	NIXFV45McW6jc3WgRZN{[Xl?	NG\UN\|UyKM7:TR?=	NUXlc3FlOSCq	MnrESG1UVw>?	MmnOTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIFPGWHIheHKxdHXpckBt\X[nbB?=	MVyxPVk3Pjd6OR?=
Primary bronchial epithelial cell	NEPhPFlMcW6jc3WgRZN{[Xl?	NH7JfpEyKM7:TR?=	M3zZS\|I1KGh?	MUXEUXNQ	MV7Jcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W\|c3XkJIF{KGmwZIXjeIlwdiCxZjDteZRidnRiRnTlcJRiPTB6IFPGWHIheHKxdHXpckBieGmlYXygd5Vz\mGlZTDsc4NidGm8YYTpc44>	NIXJT4UyQTl4Nke4PS=>
CFBE41o-	NX7yXYg5U2mwYYPlJGF{e2G7	MnjNNUDPxE1?	NYrncoZ3PSCmYYnz	MVvEUXNQ	MX\Jcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIIP0ZYJqdGm8YYTpc44hd2ZiRnTlcJRiPTB6IFPGWHIheHKxdHXpci=>	Ml\XNVk6PjZ5OEm=
CFBE41o-	MWjLbY5ie2ViQYPzZZk>	NV7icWZtOSEQvF2=	NXG0N48yOjRiaB?=	MXLEUXNQ	MmTXTY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDG[IVtfGF3MEigR2ZVWiCycn;0[YlvKHS{YX\mbYNscW6p	Ml71NVk6PjZ5OEm=
CFBE41o-	NFTtV\|RMcW6jc3WgRZN{[Xl?	MU[1JO69VQ>?	MYqyOEBp	NFX6c41FVVOR	NYHyPWlbUW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBz[XSnIH;mJI1ifHW{YYTpc44hd2ZiQ1\UVkBxem:2ZXnuJJRwKGm2czDncJlkd2[xcn2=	NIPrWYkyQTl4Nke4PS=>
CFBE41o-	NEnueHNMcW6jc3WgRZN{[Xl?	MYm1JO69VQ>?	MUKyOEBp	M3HZd2ROW09?	MVfJcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIIP0ZYJqdGm2eTDv[kBH\GWudHG1NFghS0[WUjDwdo91\Wmw	MVWxPVk3Pjd6OR?=
CFBE41o-	M1zFVmtqdmG\|ZTDBd5NigQ>?	NVTPUnB6PSEQvF2=	M3ziUlI1KGh?	NV3t[VR5TE2VTx?=	MXvJcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W\|c3XkJIF{KGOxcoLlZ5Rqd25ib3[gcZV1[W62IF\k[Yx1[TVyODDDSnRTKHS{YX\mbYNscW6pIITvJINmdGxic4Xy[oFk\SCjczDncJlkd2[xcn2=	M2jYVlE6QTZ4N{i5
Primary bronchial epithelial cell	NHzRT3ZMcW6jc3WgRZN{[Xl?	NU\GfnFUPSEQvF2=	M1uxV\|I1KGh?	Moe4SG1UVw>?	NILBN5lKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJI12fGGwdDDG[IVtfGF3MEigR2ZVWiCycn;0[YlvKGGyaXPhcEB{fXKoYXPlJIxw[2GuaYrheIlwdg>?	MX2xPVk3Pjd6OR?=
Primary bronchial epithelial cell	NFrLXVZMcW6jc3WgRZN{[Xl?	MkP3NUDPxE1?	MXG5OkBp	Mk\ESG1UVw>?	NGL1NJhKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJNpd3K2IHPpdoN2cXRiY4XydoVvfHN?	MonoNVk6PjZ5OEm=
BxPC3	MnTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Ml31O\|IhcA>?		M{m0XWlEPTB;Mj63JO69VQ>?	MUeyNFE1Ozd5OB?=
CAL27	NXXCVFJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnTBO\|IhcA>?		M2G5OmlEPTB;Mz63NkDPxE1?	MXyyNFE1Ozd5OB?=
Capan1	NF:4Xm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmXpO\|IhcA>?		NYLrepRLUUN3ME23MlMh\|ryP	M3HTUlIxOTR\|N{e4
HCC827	NI\RR5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NF7Rb3A4OiCq		MXTJR\|UxRTFwODFOwG0>	M3PoeFIxOTR\|N{e4
LNCAP	MoLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4foPFczKGh?		M{HZPWlEPTB;MD61PEDPxE1?	Ml3lNlAyPDN5N{i=
NCI-H2122	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4r2cVczKGh?		NUDoNZppUUN3ME23MlUh\|ryP	M3PFT\|IxOTR\|N{e4
NCI-H358	NWXDW3NOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVrXTIJJPzJiaB?=		NVXtSlhLUUN3ME2yMlUh\|ryP	NYHpRVZlOjBzNEO3O\|g>
SCC15	NFK1XYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXj0WJNrPzJiaB?=		NXWxcFFZUUN3ME2yMlQ6KM7:TR?=	NX7XfHpiOjBzNEO3O\|g>
SCC25	NGPWeVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MU[3NkBp		MYTJR\|UxRTFwOUOg{txO	NHmwN3YzODF2M{e3PC=>
SKHEP1	MlrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWTZe4J2PzJiaB?=		MWDJR\|UxRTNwNE[g{txO	M16weVIxOTR\|N{e4
BJ	NXLic2NrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;XflYyODBizszN	MkLBOFghcA>?	M3Pyd2ROW09?	NEjlV3FIem:5dHigbY5pcWKrdHnvckBifCByLkC1JJRwKDFyMDD1US=>	MoDnNlAyPDN6NEC=
MUF	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELRU5UyODBizszN	MYq0PEBp	NHL3NIpFVVOR	MUjHdo94fGhiaX7obYJqfGmxbjDheEAxNjB3IITvJFExOCC3TR?=	MV:yNFE1Ozh2MB?=
Caco-2	NYH4dHNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7pPZMyODBizszN	NYLM[mIyPDiq	MmLSSG1UVw>?	MVLJR\|UxRThwMTFOwG0>	NX21dWJsOjBzNEO4OFA>
Caco-2	NXrF[3dbU2mwYYPlJGF{e2G7	M1;BOFUh\|ryP	M4PiXVQhcA>?	M3u2VWROW09?	MnmzTY5lfWO2aX;uJI9nKEiGQVOtcYVlcWG2ZXSgbIl{fG:wZTDhZ4V1gWyjdHnvckBKSzVyIH;mJFAvODN5IN88US=>	MlvUNlAyPDN6NEC=
Caco-2	MU\LbY5ie2ViQYPzZZk>	MW[wMlMyPiCwTTD0c{A{OS54IN88US=>	NEDhO2E1KGh?	NH7YbGlFVVOR	NITwPWlGgCC4aY\vJIlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{Gge4l1cCCLQ{WwJI9nKDBwMUG5JO69VQ>?	NHHad4UzODF2M{i0NC=>
Caco-2	MmrrT4lv[XOnIFHzd4F6	MWWwMlMyPiCwTTD0c{A{OS54IN88US=>	MV[0JIg>	NYrDeZFVTE2VTx?=	MonlSZghfmm4bzDpcohq[mm2aX;uJI9nKGi3bXHuJGhFSUN\|IIfpeIghUUN3MDDv[kAxNjF2NzFOwG0>	NWrMSnF2OjBzNEO4OFA>
Caco-2	NIKwPZNMcW6jc3WgRZN{[Xl?	MUC2MlMzKG6PIITvJFY{OiEQvF2=	NHHsRYQ1KGh?	M2C4[WROW09?	M2K0SmV5KH[rdn:gbY5pcWKrdHnvckBw\iCqdX3hckBJTEGFNTD3bZRpKEmFNUCgc4YhOTJwNjFOwG0>	MlnLNlAyPDN6NEC=
Caco-2	M4XWbWtqdmG\|ZTDBd5NigQ>?	NELFVW43NjN{IH7NJJRwKDZ\|MjFOwG0>	MXG0JIg>	M33JfGROW09?	MUPFfEB3cX[xIHnubIljcXSrb36gc4YhcHWvYX6gTGRCSzdid3n0bEBKSzVyIH;mJFQyKM7:TR?=	NHTCZlIzODF2M{i0NC=>
Caco-2	M4DBOmtqdmG\|ZTDBd5NigQ>?	NYjYO2NFOC5\|MU[gcm0hfG9iM{GuOkDPxE1?	MYq0JIg>	MnjZSG1UVw>?	MoHISZghfmm4bzDpcohq[mm2aX;uJI9nKGi3bXHuJGhFSUN4	MoHxNlAyPDN6NEC=
HepG2	MUjLbY5ie2ViQYPzZZk>	M1LBPFUh\|ryP	MVS2bC=>	MULEUXNQ	NXzaUFhWUW6mdXP0bY9vKG:oIFjERWMudWWmaXH0[YQhcGm\|dH;u[UBi[2W2eXzheIlwdg>?	MnPhNlAyPDN6NEC=
HepG2	NU[2ToVZU2mwYYPlJGF{e2G7	MVq1JO69VQ>?	MYK2bC=>	NUXkOGkxTE2VTx?=	MWjJcoR2[3Srb36gc4YhUESDQz3t[YRq[XSnZDDobZN1d26nIHj5dIVz[WOndInsZZRqd25?	NEXIXGEzODF2M{i0NC=>
HepG2	MX\LbY5ie2ViQYPzZZk>	MVS1JO69VQ>?	Mn;3Oog>	NXXxfopHTE2VTx?=	NGW1fGtKdmS3Y4Tpc44hd2ZiSFTBR{1u\WSrYYTl[EBidHCqYT30eYJ2dGmwIHHj[ZR6dGG2aX;u	NVrNUWlVOjBzNEO4OFA>
HepG2	Ml[2T4lv[XOnIFHzd4F6	NXe0eY9MPSEQvF2=	NWHQeFdGPmh?	NHXyUGZFVVOR	NF76O2FKdmS3Y4Tpc44hd2ZiSFTBR{1u\WSrYYTl[EBJOy:KNDDobZN1d26nIHHj[ZR6dGG2aX;u	M{SyZVIxOTR\|OESw
COLO205	M4nieGtqdmG\|ZTDBd5NigQ>?	MXKxNEDPxE1?	MmPPNlQhcA>?	NWnVXYlFTE2VTx?=	MVLJcohq[mm2aX;uJI9nKEiGQVOxJIF{e2W\|c3XkJIF{KGmwZIXjeIlwdiCxZjDobZN1d26nIFizJIFk\XS7bHH0bY9vKHerdHigTWM2OCCxZjCyMlIh\|ryP	MmDpNlA1PTF\|N{i=
SCC4	MoPMT4lv[XOnIFHzd4F6	NE\vc24yKM7:TR?=	NXXFWVFnOjSq		MkXyTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIIT1ZpVtcW5iYXPleJlt[XSrb36=	NIi2NoMzODR3MkKyOS=>
SCC4	NV3kPIx{U2mwYYPlJGF{e2G7	MYWxJO69VQ>?	NYTOWW5YOjSq		NW\OU2NDUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgZYNmfHmuYYTpc44>	MWqyNFQ2OjJ{NR?=
SCC4	MYfGeY5kfGmxbjDBd5NigQ>?	MXGxJO69VQ>?	NVTTVoIzPSCvaX6=		MXnB[49vcXO2IHHjeIl3cXS7IHH0JHZFWiCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhS1mSMkSg[4Vv\SCneIDy[ZN{cW:w	MXSyNFQ2OjJ{NR?=
NB4	MknGSpVv[3Srb36gRZN{[Xl?	M3;MRVUh\|ryP	M2LwTlI1KGh?	M2HzSmROW09?	NIPxemdE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDhZ4N2dXWuYYTpc44h[XRicILlMWcyKHCqYYPl	MmGzNlA1QTF2NEC=
NB4	NHHxOotMcW6jc3WgRZN{[Xl?	M1q3dVUh\|ryP	M{T5W\|I1KGh?	M1PNO2ROW09?	M{n6TmlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDhZ4V1gWyjdHWgeJVjfWyrbjDs[ZZmdA>?	M3\tZlIxPDlzNESw
NB4	NVfrO3kyTnWwY4Tpc44hSXO\|YYm=	NGrEVo02KM7:TR?=	MXGyOEBp	Ml;0SG1UVw>?	NGXI[2JKdmS3Y4Tpc44hd2ZicEKxW2FHOS:FSWCxJIV5eHKnc4Ppc44>	MXuyNFQ6OTR2MB?=
NB4	NFPMSnJMcW6jc3WgRZN{[Xl?	MX61JO69VQ>?	MnLsNlQhcA>?	NHOxW4tFVVOR	NF\aUJNKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIN{Bi[2W2eXzheIlwdg>?	MWWyNFQ6OTR2MB?=
NUGC3	M2TYPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jvXWdKPTB;Mj65OEDPxE1?	NGrnOWIzODh3MEm3NS=>
A549	NGqyRnpHfW6ldHnvckBCe3OjeR?=	MnfkOUDPxE1?	NVft[WJMOyCq	MYrEUXNQ	NWjwSpM1UW6mdXP0bY9vKG:oIHH1eI9xcGGpeTDpckBpfW2jbjDBOVQ6KGOnbHzzJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIFzDN2lK	MWCyNFg2PTJyOB?=
HUT78	NXfSVlZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUDNVm1OPzJiaB?=	NGXpToZFVVOR	NVHkc5A2T0l3ME2wMlMh\|ryP	M1[4XlIxQDh2MkC4
U937	M1u0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlrXO\|IhcA>?	NXrSb2pETE2VTx?=	NVHIdGVsT0l3ME2wMlM6KM7:TR?=	Mnf6NlA5QDR{MEi=
A431	NYX2R2xqS3m2b4TvfIlkKEG\|c3H5		NGP2ZWo4OiCq		NEK5RVREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPDNzIHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJGVITlJid3n0bEBKSzVyIH;mJFQvOiEQvF2=	NFnCfFEzOTB6ME[yPS=>
A549	NULxZlBtS3m2b4TvfIlkKEG\|c3H5		MWG3NkBp		MojxR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{BwfmW{ZYjwdoV{e2mwZzDISGFEKHerdHigTWM2OCCxZjCxMlgh\|ryP	NYHRR3p5OjFyOEC2Nlk>
CAL27	M3\obmN6fG:2b4jpZ{BCe3OjeR?=		MnywO\|IhcA>?		M3XRcmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNCVDJ5IHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJGVITlJid3n0bEBKSzVyIH;mJFMvOiEQvF2=	MlOyNlExQDB4Mkm=
HeLa	NFH0O2hEgXSxdH;4bYMhSXO\|YYm=		M{OzVVczKGh?		MlHHR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{BwfmW{ZYjwdoV{e2mwZzDISGFEKHerdHigTWM2OCCxZjCxMlUh\|ryP	M{jLOlIyODhyNkK5
Sf21	MnTvT4lv[XOnIFHzd4F6		MWizJIg>		Mm\iTY5pcWKrdHnvckBw\iCIbHHnJJRi\2enZDDoeY1idiC{ZXPvcYJqdmGwdDDISGFEQCCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFEvOiEQvF2=	NXOxOWV6OjFyOEC2Nlk>
SKBR3	NFK2[o5EgXSxdH;4bYMhSXO\|YYm=		Mo[0O\|IhcA>?		MorlR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2tDWjNiY3XscJMhd3[ncnX4dJJme3OrbnegTGVTOiC5aYToJGlEPTBib3[gNk43KM7:TR?=	NH7zcFkzOTB6ME[yPS=>
SKOV3	M4XxfmN6fG:2b4jpZ{BCe3OjeR?=		MVS3NkBp		NUiwTFdxS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0uRVkOgZ4VtdHNib4\ldoV5eHKnc4PpcochUEWUMjD3bZRpKEmFNUCgc4YhOi5{IN88US=>	NGqwW5UzOTB6ME[yPS=>
COR-L23	NX\QbJhlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWj1[olEOTBizszN	NX\CUG1rPzJiaB?=	MVLEUXNQ	NGfieZhIUTVyPUGuNUDPxE1?	NXLaRWFrOjFyOEC2OFc>
DU145	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{O1b\|ExKM7:TR?=	M{PyS\|czKGh?	MoX1SG1UVw>?	MnTQS2k2OD1zLkC1JO69VQ>?	MonyNlExQDB4NEe=
LoVo	M3WxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUCxZ4RiOTBizszN	NF\4ZoQ4OiCq	NHriNIlFVVOR	MVXHTVUxRTFwNzFOwG0>	NUHSV\|lnOjFyOEC2OFc>
MCR5-SV2	NW\Rc3hwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVvteYtXOTBizszN	NI\nXIc4OiCq	M4jhWGROW09?	NVTHVIhkT0l3ME2yMlEh\|ryP	MUKyNVA5ODZ2Nx?=
HCT116	MknxT4lv[XOnIFHzd4F6	NGLUNIo{OCEQvF2=	M3jVRlMxKGh?	MmjuSG1UVw>?	M1fKcWlvcGmkaYTpc44hd2ZiSFTBR\|Yh[XO\|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJIFteGijLYT1ZpVtcW5iYXPleJlt[XSrb36=	MXmyNVA5ODZ2Nx?=
HCT116	M4LEPWtqdmG\|ZTDBd5NigQ>?	NIjab2s{OCEQvF2=	M37yOVMxKGh?	NGLZWFdFVVOR	NEixbVJKdmirYnn0bY9vKG:oIFjERWMyKGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBpcXO2b37lJGg{UzliYXPleJlt[XSrb36=	NYjVdnlnOjFyOEC2OFc>
U937	MoDvT4lv[XOnIFHzd4F6	M{PNV\|Uh\|ryP	NFPUTnYzPCCq	M13rT2ROW09?	NUCyVphlUW6qaXLpeIlwdiCxZjDobZN1d26nIHHj[ZR6dHS{YX7z[oVz[XOnIHHzd4V{e2WmIHHzJIlv[3KnYYPlJI9nKGGlZYT5cIF1cW:wIH;mJIhqe3SxbnWgTFMh[XRiS{m=	M{n6Z\|IyOjl{NEmy
U937	M2G0V2tqdmG\|ZTDBd5NigQ>?	MkHrOUDPxE1?	MXSyOEBp	MYfEUXNQ	M2izbGlvcGmkaYTpc44hd2ZiaHnzeI9v\SCjY3X0fYx1emGwc3\ldoF{\SCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDv[kBi[2W2eXzheIlwdiCxZjDobZN1d26nIFizJIF1KEtzOB?=	NYXCbnF{OjF{OUK0PVI>
U937	NEe1c5pMcW6jc3WgRZN{[Xl?	NHnObow2KM7:TR?=	Ml\FNlQhcA>?	NFHDXldFVVOR	NIP5N\|dKdmirYnn0bY9vKG:oIHjpd5RwdmViYXPleJltfHKjboPm[ZJie2ViYYPz[ZN{\WRiYYOgbY5kemWjc3Wgc4YheGGwLXHj[ZR6dGG2ZXSgbIl{fG:wZTDIOEBt\X[nbB?=	M4fyO\|IyOjl{NEmy
U937	NEP2cYVMcW6jc3WgRZN{[Xl?	NEPSNpA2KM7:TR?=	NF3RPIYyPSCvaX6=	MVrEUXNQ	Mn3pTY5pcWKrdHnvckBw\iCqaYP0c45mKGGlZYT5cJRz[W6\|ZnXyZZNmKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIH;mJIhqe3SxbnWgTFMh[WOndInsZZRqd25ibHX2[Yw>	M3nGe\|IyOjl{NEmy
A2780	NV25e2g4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mn7LPVYhcA>?	NHy4eINFVVOR	NUnSOYtGUUN3ME2xMlYzKM7:TR?=	NFOwS2MzOTZ\|NESzNC=>
COLO205	NFTHUWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4TYT\|k3KGh?	NEXvdVBFVVOR	M1\TUmlEPTB;Mj6xNkDPxE1?	M2XLWVIyPjN2NEOw
Hep3B	M2\TNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGrjV5I1QCCq	MYfEUXNQ	M4jic2dKPTB;MT6yNUDPxE1?	M2TwTlIyPzF{MUS2
GM11272	MWLGeY5kfGmxbjDBd5NigQ>?	NH64XnMyODBibl2=	MVu3NkBp	NGnsZnRFVVOR	M2fNZnJm[WO2aY\heIlwdiCxZjDN[WNxOiCvdYThcpQh\XiycnXzd4lwdiCjdDCxNEB1dyBzMECgcm0>	NXiyVJppOjF6NEC3NVY>
CFBE41o	NEDIcoRMcW6jc3WgRZN{[Xl?	NE\pbIY2KM7:TR?=		M3j1fmROW09?	MkD2SI94diC{ZXf1cIF1cW:wIH;mJGhFSUN5IHH0JFAvOiC2bzC1JJVO	NYDNRWFJOjF7OES5OVg>
CFBE41o	NV21cYRrTnWwY4Tpc44hSXO\|YYm=	MX6xJO69VQ>?	NXLHb5BvOjRiaB?=	MVHEUXNQ	Ml\tVoV{fG:{YYTpc44hd2ZiQ1\UVkBl\Wy2YV[1NFghdXW2YX70JJRz[W[oaXPrbY5oKHSxIHPlcIwhe3W{ZnHj[UBieyCpbInjc4Zwem2\|	NV3TSYxOOjF7OES5OVg>
DU145	M2T6SGtqdmG\|ZTDBd5NigQ>?	MoDBNk42KM7:TR?=	NIW5O3QzPCCq	NITNNGtFVVOR	MX3Jcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhfXC{ZXf1cIF1cW:wIH;mJJAzOXejZkGgdJJwfGWrbjDlfJBz\XO\|aX;u	MmXKNlIzPjBzNk[=
DU145	MX7LbY5ie2ViQYPzZZk>	MXW1JO69VQ>?	NXjNU5luOjRiaB?=	NGSzNFVFVVOR	Mm\NTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGirc4TvcoUhUDRiYXPleJlt[XSrb36=	MXWyNlI3ODF4Nh?=
DU145	MVLLbY5ie2ViQYPzZZk>	Mk\6OUDPxE1?	NXfZWpVZOjRiaB?=	M1OzUWROW09?	M2ryVWlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCqaYP0c45mKEh\|IHj5dIVz[WOndInsZZRqd25?	MX6yNlI3ODF4Nh?=
786-0	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7kR\|F{Pi5{IN88US=>	MlXkO\|IhcA>?	M4XwTmROW09?	M{Th[WdKPTB;Mz6yJO69VQ>?	MU[yNlQ{PTZ4OR?=
A498	NH3BPXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXG2MlIh\|ryP	MVK3NkBp	NY\kO4dtTE2VTx?=	NWDVZYlmT0l3ME2xMlYh\|ryP	M3TISVIzPDN3Nk[5
A549/ATCC	MlyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTWWI44Pi5{IN88US=>	M1;NSlczKGh?	NY\NbVVWTE2VTx?=	NIrmUGdIUTVyPUGuOkDPxE1?	MViyNlQ{PTZ4OR?=
ACHN	M3XBfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LnZ\|YvOiEQvF2=	M2nOSFczKGh?	NIjFR4dFVVOR	MYPHTVUxRTFwMzFOwG0>	MVuyNlQ{PTZ4OR?=
BT549	NWf2Wm1DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TORlYvOiEQvF2=	NETNepM4OiCq	NEL6UYVFVVOR	MVHHTVUxRTFwMzFOwG0>	NFqxcnIzOjR\|NU[2PS=>
EKVX	NHe5dG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVS2MlIh\|ryP	M3zpelczKGh?	M3nzSmROW09?	NFTzWmdIUTVyPUGuN{DPxE1?	M{XaNlIzPDN3Nk[5
HCT15	NIf1RnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\YSVYvOiEQvF2=	NIj5S\|I4OiCq	Mo\aSG1UVw>?	NV[zcIJ5T0l3ME2yMlUh\|ryP	MkfyNlI1OzV4Nkm=
HOP92	NVXTWFQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2jyXFYvOiEQvF2=	MWe3NkBp	M2TtTmROW09?	NV74[YpST0l3ME20JO69VQ>?	NX\2THNDOjJ2M{W2Olk>
IGROV1	M33wU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkGwOk4zKM7:TR?=	M{e5NlczKGh?	NWnCVZdRTE2VTx?=	NULHfY4xT0l3ME2xMlMh\|ryP	M2XGR\|IzPDN3Nk[5
LOXIMVI	M1PMbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWq2MlIh\|ryP	NWXHenpKPzJiaB?=	NUD0dnE{TE2VTx?=	NIe2clhIUTVyPUGg{txO	NV\EZXY2OjJ2M{W2Olk>
M14	MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWS2[G9jPi5{IN88US=>	M4DIVFczKGh?	NY[zdWl6TE2VTx?=	NGjC[\|BIUTVyPUGuN{DPxE1?	MX6yNlQ{PTZ4OR?=
MALME-3M	MoHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW[2MlIh\|ryP	M33tUFczKGh?	MlLXSG1UVw>?	M1ruT2dKPTB;MD6zNkDPxE1?	MVyyNlQ{PTZ4OR?=
MCF10A	MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPXVJFVPi5{IN88US=>	MVG0PEBp	M{PqWGROW09?	MmnPS2k2OD17Lk[g{txO	M2PwPFIzPDN3Nk[5
MDA-MB-435	NUX2dIJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDMZ3NlPi5{IN88US=>	M1rt[FczKGh?	NG\Lc29FVVOR	MVjHTVUxRTBwNTFOwG0>	NVP0NZJ6OjJ2M{W2Olk>
MDA-MB-468	MlzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV62MlIh\|ryP	M4XQZlczKGh?	MkC2SG1UVw>?	MWXHTVUxRTBwNkOg{txO	MUOyNlQ{PTZ4OR?=
MOLT4	NFT4UJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mki2Ok4zKM7:TR?=	M2DjRlczKGh?	NWTVdGVFTE2VTx?=	NUDTbmNJT0l3ME2wMlQh\|ryP	MVSyNlQ{PTZ4OR?=
NCI-ADR-RES	M4LFe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXT6[lJRPi5{IN88US=>	Mn3UO\|IhcA>?	MYrEUXNQ	NEjLNY1IUTVyPUCuNVYh\|ryP	M3LNTVIzPDN3Nk[5
NCI-H23	NVXsUVR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\QVFk3NjJizszN	MUK3NkBp	M4\I[WROW09?	M3\2d2dKPTB;MTFOwG0>	NYXK[\|d2OjJ2M{W2Olk>
NCI-H322M	MmLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LRdFYvOiEQvF2=	NYnBNVNEPzJiaB?=	MnzMSG1UVw>?	NX7oRYVHT0l3ME2wMlc6KM7:TR?=	NIPUUWszOjR\|NU[2PS=>
NCI-H460	NX:xOFZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3kOk4zKM7:TR?=	MWK3NkBp	NYDqV4JoTE2VTx?=	MXvHTVUxRTBwN{mg{txO	NW\TXmh5OjJ2M{W2Olk>
NCI-H522	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkSzOk4zKM7:TR?=	NYeyeWdJPzJiaB?=	MWHEUXNQ	NIr1eWlIUTVyPUCuOUDPxE1?	NYfwdlVHOjJ2M{W2Olk>
OVCAR3	NUPWd4lTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEH5d4Q3NjJizszN	M3mxOVczKGh?	NFv4OJFFVVOR	NIfHN49IUTVyPUGuN{DPxE1?	NIPETZYzOjR\|NU[2PS=>
OVCAR4	NGrmNldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEO5U5o3NjJizszN	NHvCfWc4OiCq	NVz1PZVETE2VTx?=	M1vmTGdKPTB;NDFOwG0>	M1HKZlIzPDN3Nk[5
OVCAR5	M{XKeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYfY[ZV7Pi5{IN88US=>	MUi3NkBp	NHq5N\|hFVVOR	MXXHTVUxRTBwN{mg{txO	MmTVNlI1OzV4Nkm=
OVCAR8	MoL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV[1eplVPi5{IN88US=>	M1\uOFczKGh?	MkTQSG1UVw>?	NW\S[mNOT0l3ME2wMlUh\|ryP	M2fOfVIzPDN3Nk[5
RXF393	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17ae\|YvOiEQvF2=	MWW3NkBp	MUTEUXNQ	MXLHTVUxRTFwMzFOwG0>	Ml7yNlI1OzV4Nkm=
SF268	M1fGXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF[2W\|g3NjJizszN	MYi3NkBp	MUHEUXNQ	MXjHTVUxRTFwNjFOwG0>	NIXPbVgzOjR\|NU[2PS=>
SF295	M1foNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mni4Ok4zKM7:TR?=	Ml7RO\|IhcA>?	MXPEUXNQ	M3zwfGdKPTB;MT62JO69VQ>?	NEjkcWQzOjR\|NU[2PS=>
SF539	MlHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fKT\|YvOiEQvF2=	MXe3NkBp	Mmm1SG1UVw>?	NIPoOGFIUTVyPUKg{txO	NYTZS3BQOjJ2M{W2Olk>
SK-MEL-2	MoGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWK2MlIh\|ryP	NH;JOnQ4OiCq	M3XCS2ROW09?	MonkS2k2OD1zLkOg{txO	NFTi[GgzOjR\|NU[2PS=>
SK-MEL-28	MnTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWHXc3NmPi5{IN88US=>	MVu3NkBp	MVLEUXNQ	NWrEOlhsT0l3ME2xJO69VQ>?	MVOyNlQ{PTZ4OR?=
SK-MEL-5	NIfS[3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnibGs3NjJizszN	NWfHcFRNPzJiaB?=	Mn7qSG1UVw>?	MYrHTVUxRTBwNkOg{txO	NE\DbVczOjR\|NU[2PS=>
SKOV3	NEHicotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDIUGJ{Pi5{IN88US=>	MYe3NkBp	NXjJXXRqTE2VTx?=	NVzjd\|ZUT0l3ME2xJO69VQ>?	M4\sVVIzPDN3Nk[5
SN12C	MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLoOk4zKM7:TR?=	NWLo[4tZPzJiaB?=	NHPLdoRFVVOR	Mn7NS2k2OD1{IN88US=>	NYTyT4pTOjJ2M{W2Olk>
SNB19	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1TxdlYvOiEQvF2=	MYC3NkBp	NWL4WYc3TE2VTx?=	MkCyS2k2OD1yLk[zJO69VQ>?	NGDRO2szOjR\|NU[2PS=>
SNB75	Ml\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHae4VuPi5{IN88US=>	M4DNNVczKGh?	MlvxSG1UVw>?	NVHwemRpT0l3ME2wMlc6KM7:TR?=	MlrwNlI1OzV4Nkm=
SR	NXvlWY1WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M13oR\|YvOiEQvF2=	MXm3NkBp	MnTmSG1UVw>?	MmLQS2k2OD1yLkSg{txO	NV\C[HdQOjJ2M{W2Olk>
T47D	MmXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXheW9NPi5{IN88US=>	M2nFNFczKGh?	NUHieW06TE2VTx?=	M1TVVGdKPTB;MD61JO69VQ>?	NEfEWW4zOjR\|NU[2PS=>
TK10	NVfDW\|JST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTXTldWPi5{IN88US=>	MofJO\|IhcA>?	M2DVWGROW09?	NXTHSWY4T0l3ME2wMlY{KM7:TR?=	M4fxV\|IzPDN3Nk[5
UACC257	M2C0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfaOk4zKM7:TR?=	MWS3NkBp	M2K3cmROW09?	MmLxS2k2OD1yLkWg{txO	NFyz[oYzOjR\|NU[2PS=>
UACC62	NYW2R\|ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW[2MlIh\|ryP	NXfKOFlwPzJiaB?=	MnTwSG1UVw>?	MXPHTVUxRTBwNDFOwG0>	NITJPYszOjR\|NU[2PS=>
UO31	NIS5fnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TOelYvOiEQvF2=	Mnn4O\|IhcA>?	MXnEUXNQ	MWnHTVUxRTBwNTFOwG0>	NHXRZZUzOjR\|NU[2PS=>
Hep3B	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUfUfpZZPDhiaB?=	NI\hb29FVVOR	MknQS2k2OD1yLk[5JO69VQ>?	M2TaXFIzPDN7OE[z
BE(2)-C	NFPKVW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXjVSHVyPzJiaB?=	NVW2S\|l4TE2VTx?=	M4XqPGlEPzB;MjFOwG0>	MoDhNlI6OzJ\|MU[=
Bel7402	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHfpR3A4OiCq	NYT2RYk{TE2VTx?=	NUfJN5hHT0l7ME2xO{DPxE1?	MkTaNlMxPjF\|N{[=
Bel7404	MlfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NETsZ2E4OiCq	MV;EUXNQ	NXL1NpY2T0l7ME2xPEDPxE1?	MUSyN\|A3OTN5Nh?=
BGC823	M{TDWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnHiO\|IhcA>?	MUjEUXNQ	M2HrRWdKQTB;Nz61JO69VQ>?	NYryVlZXOjNyNkGzO\|Y>
MGC803	NY\WZpdmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWjyPYhjPzJiaB?=	M2HNSWROW09?	MWrHTVkxRTFyLkig{txO	M4\1NVI{ODZzM{e2
SGC7901	NXviOHFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHXZNXU4OiCq	MnLtSG1UVw>?	Mmn4S2k6OD17LkSg{txO	NYrUeoxmOjNyNkGzO\|Y>
SKHEP1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXHhUpFnPzJiaB?=	MkTrSG1UVw>?	NVyxV2Y2T0l7ME2xO{DPxE1?	MnH5NlMxPjF\|N{[=
SMMC7721	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWDi[IhiPzJiaB?=	NETM[m5FVVOR	NFOxSIxIUTlyPUKwJO69VQ>?	NVfwc4VKOjNyNkGzO\|Y>
NUGC3	NYqxO5RPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjFeXoyOCEQvF2=			MXjHTV0zNjl2IN88US=>	MkDVNlMyPjN\|M{K=
A2780 CisR	MWLLbY5ie2ViQYPzZZk>		M4TKbVE5KGh?		NXLH[GFLUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlQ1KM7:TR?=	M2TLO\|I{OjV{NkCz
CAL27 sens	NGjrUGdMcW6jc3WgRZN{[Xl?		NHHyNYQyQCCq		NWTQbpJvUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlM3KM7:TR?=	M3rSSVI{OjV{NkCz
CAL27 CisR	M{nIUWtqdmG\|ZTDBd5NigQ>?		NFH2cHMyQCCq		NH\6c3lKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR\|UxKG:oIECuOlEh\|ryP	NI[4cnUzOzJ3Mk[wNy=>
KYSE-510 CisR	NELob3VMcW6jc3WgRZN{[Xl?		MUKxPEBp		NV\ie\|hjUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlU6KM7:TR?=	NHHWd4ozOzJ3Mk[wNy=>
KYSE-510 sens	MXPLbY5ie2ViQYPzZZk>		M3T2[FE5KGh?		M2T6VWlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD63JO69VQ>?	NVn6U2FvOjN{NUK2NFM>
MDA-MB-231 sens	NGHVNWlMcW6jc3WgRZN{[Xl?		NH;TSGcyQCCq		M3n1RmlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD62NUDPxE1?	M3m4T\|I{OjV{NkCz
MDA-MB-231 CisR	MVHLbY5ie2ViQYPzZZk>		NWrWSmxSOThiaB?=		NGLMNFhKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR\|UxKG:oIECuOlEh\|ryP	M2jpT\|I{OjV{NkCz
ES2	NFLBUm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWLlZ4RXPDhiaB?=	NIq5cZBFVVOR	MnnLTWM2OD1zMj63JO69VQ>?	NUnOdXBqOjN2OUO0OFk>
MDA-MB-231	MYfLbY5ie2ViQYPzZZk>	M2mz[FExKM7:TR?=	MUGzNEBucW5?	NFrBcYNFVVOR	NGSwRYNKdmirYnn0bY9vKG:oIFjERWMz[Q>?	MYOyN\|Q6OzR2OR?=
MDA-MB-231	NV3kUWIyU2mwYYPlJGF{e2G7	NIPXZZQyKM7:TR?=	NHT0[ZgzPCCq	NH3GTWVFVVOR	NIfnNldKdmirYnn0bY9vKG:oIFjERWM3KGG\|c3Xzd4VlKGG\|IHHj[ZR6dGG2aX;uJIxmfmWuczDv[kB1fWK3bHnu	MnPkNlM1QTN2NEm=
HS68	NYnzb\|k2S3m2b4TvfIlkKEG\|c3H5	NULMSnF{OTBizszN	NFnPS5A4OiCq	MYXEUXNQ	MU\JR\|UxRTRwNjFOwG0>	MkXZNlM2PzB3NEK=
MEF	MlKyR5l1d3SxeHnjJGF{e2G7	M{\VNlExKM7:TR?=	M2PseFczKGh?	NUew[nZNTE2VTx?=	M2f0TWlEPTB;ND60JO69VQ>?	MYCyN\|U4ODV2Mh?=
BGC823	NFflS2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnPVSG1UVw>?	Mmq4S2k2OD1\|LkC5JO69VQ>?	M4j5VVI{PjBzN{C2
High5	Mn;yT4lv[XOnIFHzd4F6		MorPNlQhcA>?		NXjLOlRwUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDISGFEPiC5aYToJGlEPTBib3[gNE4xQSEQvF2=	MkH1NlM3ODJ3MkO=
High5	MmfRT4lv[XOnIFHzd4F6		NGPmWoszPCCq		MnrnTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKRFHDNUB4cXSqIFnDOVAhd2ZiMD6xNkDPxE1?	M3fFZ\|I{PjB{NUKz
High5	NX[xZ2lDU2mwYYPlJGF{e2G7		MYWyOEBp		NFnIWJRKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IFjERWM{KHerdHigTWM2OCCxZjCwMlE4KM7:TR?=	NH3pWnQzOzZyMkWyNy=>
A549	NV;nWoJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NY\hd4NXTE2VTx?=	NGXNe5FKSzVyPUGuNFc6KM7:TR?=	Mn\KNlM3PDR{MUC=
HCT116	NWfuSXc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYTEUXNQ	NFHUVG5KSzVyPUCuO\|U4KM7:TR?=	MX[yN\|Y1PDJzMB?=
K562	NXvjU2dlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1rjRmROW09?	MY\JR\|UxRTBwNkS1JO69VQ>?	MUOyN\|Y1PDJzMB?=
GBC-SD	NUe5XIZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEWyWXY2KM7:TR?=	MlPKO\|IhcA>?	MYTEUXNQ	NG\vdHVKSzVyPUG0Mlgh\|ryP	NYrVelRqOjN5MEeyOlA>
HGC27	Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXi4fnl1PSEQvF2=	M4Xrd\|czKGh?	M{LQc2ROW09?	NWi4fHBUUUN3ME21MlQh\|ryP	NXHRbpVoOjN5MEeyOlA>
HL60	NXzzNHM6U2mwYYPlJGF{e2G7	MWC1JO69VQ>?	MmTCNlQhcA>?	NFXuXnFFVVOR	MYPJcohq[mm2aX;uJI9nKEiGQVO=	NGf0eVczOzdyN{K2NC=>
Vero	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3LUc\|czKGh?	NVjp[2QyTE2VTx?=	MV\JR\|UxRTBwOTFOwG0>	MofFNlM4QDZ2NUK=
NCI60	M4\yfGN6fG:2b4jpZ{BCe3OjeR?=		NIDpVlQ1QCCq	M3qxR2ROW09?	MV7HTV0xNjV\|IN88US=>	MmPSNlQxOTV\|Mke=
SW620	MXXDfZRwfG:6aXOgRZN{[Xl?		MnfZOFghcA>?	M3TvTGROW09?	M1exZ2dKRTBwNUSg{txO	M3TYVlI1ODF3M{K3
U251	NGD3dHBEgXSxdH;4bYMhSXO\|YYm=		MWK0PEBp	MmXHSG1UVw>?	NVntRVY5T0l;MT61N{DPxE1?	M{DoTlI1ODF3M{K3
KM12	NH64copEgXSxdH;4bYMhSXO\|YYm=		M3POd\|Q5KGh?	NV\5VVJqTE2VTx?=	MVzHTV0yNjh6IN88US=>	NGn5NFgzPDBzNUOyOy=>
Hs578T	NHjlfYVEgXSxdH;4bYMhSXO\|YYm=		MYi0PEBp	NGXYWXlFVVOR	NYXqfWQxT0l;ND64N{DPxE1?	M1L5WFI1ODF3M{K3
MDA-MB-231	M4\lOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYOzXWRpPDhiaB?=		MXrJR\|UxRTBwMU[g{txO	MlW4NlQxQTVyMU[=
MCF7	NFXwSpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWi0PEBp		NGrFPIhIUT1yLkS1JO69VQ>?	MoLjNlQyOTl3NUW=
MDA-MB-435	NWHPWHBqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2jhXlQ5KGh?		NVjqbVA2T0l;MD64PEDPxE1?	NXv3PJNyOjRzMUm1OVU>
AsPC1	NXzEOI43T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TTU\|MxKM7:TR?=	MVi0PEBp	M17nb2ROW09?	MVXJR\|UxRTNwNk[g{txO	NXm4V4x6OjRzOEWzO\|g>
Jurkat E6.1	NWXiS\|g5U2mwYYPlJGF{e2G7		Mli4NkBp	Mmj2SG1UVw>?	NFvZeJNKdmirYnn0bY9vKG:oIFjERWM1KHerdHigTWM2OCCxZjCwMlA1KM7:TR?=	Mor3NlQzPjF6NkK=
KG1	NIfifXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWW0PEBp		MUTJR\|UxRTFwMUWg{txO	MYSyOFUzPTByMx?=
HEL	MlPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGKwO4M1QCCq	M{H1O2ROW09?	NXzZZYFpUUN3ME2wMlQ6KM7:TR?=	Mom3NlQ3QTRyNUW=
HSC3	MoDmR5l1d3SxeHnjJGF{e2G7		MkTMNVIhcA>?	NIroeoZFVVOR	MYDJR\|UxRTBwN{Gg{txO	MkDDNlQ4PjZ3NkC=
HT-29	M37VXWN6fG:2b4jpZ{BCe3OjeR?=		M1PObVEzKGh?	NHvHcGtFVVOR	NFnoZo1KSzVyPUCuO\|Ih\|ryP	NI\4VWYzPDd4NkW2NC=>
KB	MmjmR5l1d3SxeHnjJGF{e2G7		Mo\4NVIhcA>?	NF:zSoFFVVOR	Ml;xTWM2OD1yLke1JO69VQ>?	M3zNZlI1PzZ4NU[w
H460	NHvhS2dEgXSxdH;4bYMhSXO\|YYm=		Mkf4NVIhcA>?	MVPEUXNQ	MWnJR\|UxRTBwOEKg{txO	NF;BSI8zPDd4NkW2NC=>
MONE1	NGS5cnlEgXSxdH;4bYMhSXO\|YYm=		M4T2OFEzKGh?	MX;EUXNQ	MlrzTWM2OD1zLkG4JO69VQ>?	MYSyOFc3PjV4MB?=
MKN45	NUS3T41{S3m2b4TvfIlkKEG\|c3H5		NH7Bb4QyOiCq	M36xfGROW09?	NFPFW3RKSzVyPUGuNlUh\|ryP	NVzaWY9GOjR5Nk[1OlA>
TSGH	NFPrUG5EgXSxdH;4bYMhSXO\|YYm=		MmK0NVIhcA>?	NXPGbW5XTE2VTx?=	NYHkZ2FsUUN3ME2yMlA6KM7:TR?=	MVmyOFc3PjV4MB?=
HL60	NGnTVIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWnEfnRNPzJiaB?=	M4fqNGROW09?	MVvHTVUxRTBwOUOg{txO	M4PVR\|I1QTByNUCw
HEK293	MkfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NILSOnE4OiCq	MlPPSG1UVw>?	Mon4S2k2OD1zMzFOwG0>	NE\VdnkzPDlyMEWwNC=>
Jurkat	NWf5VFhTS3m2b4TvfIlkKEG\|c3H5	MkPZNVAxKM7:TR?=	NF3KTHc4OiCq		MnO1S2k2OD1yLkmg{txO	MXSyOFkxODd2Mx?=
GM15850	M{jobmtqdmG\|ZTDBd5NigQ>?	NHnzXWIzNjVizszN	M{DRS\|k3KGh?	NES5R21FVVOR	MkHH[I9meyCwb4SgbY5pcWKrdDDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm\|aX7lJFE1KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	Mof0NVY6OjF\|Nke=
GM15850	MXzLbY5ie2ViQYPzZZk>	MmnoNk42KM7:TR?=	MmTjPVYhcA>?	NXS0R3RvTE2VTx?=	MVjkc4V{KG6xdDDpcohq[mm2IFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgOUBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?=	NFfhc5MyPjl{MUO2Oy=>
GM15850	Ml3lT4lv[XOnIFHzd4F6	M33ZWlIvPSEQvF2=	MmDwPVYhcA>?	MVLEUXNQ	MWfkc4V{KG6xdDDpcohq[mm2IFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgNVIh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	M4WzbVE3QTJzM{[3
GM15850	NWf0NZNLU2mwYYPlJGF{e2G7	MUiyMlUh\|ryP	MYW5OkBp	M4\GemROW09?	M{nFcoRw\XNibn;0JIlvcGmkaYSgTGRCSyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBpcXO2b37lJGg{KGy7c3nu[UA6KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	NWHhWGJOOTZ7MkGzOlc>
GM15850	NEPK[JpMcW6jc3WgRZN{[Xl?	M4TFN\|IvPSEQvF2=	NGHFTG86PiCq	NX20VoFwTE2VTx?=	MXjkc4V{KG6xdDDpcohq[mm2IFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgPEBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?=	M{C1XlE3QTJzM{[3
GM15850	MW\LbY5ie2ViQYPzZZk>	M3TFUlIvPSEQvF2=	M{HkRlk3KGh?	NHvOd5dFVVOR	NHHGcIhld2W\|IH7veEBqdmirYnn0JGhFSUNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm\|dH;u[UBJPCCueYPpcoUhOTZiYXPleJlt[XSrb36gc4YhTliQIHflcoU>	MXmxOlkzOTN4Nx?=
GM15850	MV;GeY5kfGmxbjDBd5NigQ>?	NWLqfldsPSEQvF2=	MoroNVIhcA>?	NVHPeXE2TE2VTx?=	MkXObIF{KG6xIHXm[oVkfCCxbjDGXG4hdVKQQTDlfJBz\XO\|aX;u	NU[3[pZnOTZ7MkGzOlc>
U937	MWXLbY5ie2ViQYPzZZk>	M2DWOVUh\|ryP	M4TZOFI1KGh?	NGi5W2FFVVOR	MVvoZZMhdm9iZX\m[YN1KG:wIHHsdIhiKHS3YoXsbY4h[WOndInsZZRqd25?	NGjD[VgyPzR2N{e1NC=>
U937	NWLQTmxVU2mwYYPlJGF{e2G7	MkSxNUDPxE1?	M1jBO\|I1KGh?	NH;3WWhFVVOR	NHPZOXVp[XNibn:g[YZn\WO2IH;uJIFteGijIIT1ZpVtcW5iYXPleJlt[XSrb36=	MnK3NVc1PDd5NUC=
PANC1	MUTGeY5kfGmxbjDBd5NigQ>?	M3HycFEh\|ryP	NXjheI54OjRiaB?=		MYjkc4V{KG6xdDDpcoNz\WG\|ZTDpckBxOjetaYCxJIdmdmViZYjwdoV{e2mxbh?=	NYj0WIxVOTd3OEi3OFQ>
PANC1	NFXBRpZHfW6ldHnvckBCe3OjeR?=	M37zflEh\|ryP	NXWxbJd1PDhiIHi=		MVHkc4V{KG6xdDDpcoNz\WG\|ZTDpckBxOjetaYCxJIdmdmViZYjwdoV{e2mxbh?=	M1niOVE4PTh6N{S0
Caco-2	NFLyeo9HfW6ldHnvckBCe3OjeR?=	MVi1JO69VQ>?	NWXnWoJtOjRiaB?=	NGD1ZZVFVVOR	MVnkc4V{KG6xdDDpcoR2[2ViUEKxW2FHOSCpZX7lJIV5eHKnc4Ppc44>	MnHZNlAyPDN6NEC=
SCC4	NVHQRYlbTnWwY4Tpc44hSXO\|YYm=	M1eyeFEh\|ryP	NEnxSm4yOCCvaX6=	NVnCe5B[TE2VTx?=	MYroZZMhdm9iYXfvcol{fCCjY4Tpeol1gSCjdDDWSHIh[XO\|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJGN[WDJ2IHflcoUh\XiycnXzd4lwdg>?	NUm2SYZ[OjB2NUKyNlU>
A549	M2Dnd2Z2dmO2aX;uJGF{e2G7	MlXEOUDPxE1?	MUizJIg>	M{DJUmROW09?	MnfJ[I9meyCwb4SgbY5lfWOnIHH1eI9xcGGpeTDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCOQ{PJTS=>	MVqyNFg2PTJyOB?=
HCT116	MXvLbY5ie2ViQYPzZZk>	NGC5XmwxNjNizszN	MVizNEBp	NETaUW5FVVOR	MkC5[I9meyCwb4SgbY5pcWKrdDDISGFEOSCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhcGm\|dH;u[UBJO0t7IHHj[ZR6dGG2aX;u	NF7Ncm0zOTB6ME[0Oy=>
HepG2	NGHs[GxHfW6ldHnvckBCe3OjeR?=	NV\zV\|FuOTBizszN	NWjyeJVsOjRiaB?=	NXLKR5pXTE2VTx?=	NIDIbVRld2W\|IH7veEBqdmS3Y3WgZZBweHSxc3nzJIF{e2W\|c3XkJIF{KGi7cHXyZYNmfHmuYYTpc44hd2ZicEWz	MUCyNVU1QDV6Mh?=
GM11272	NY\0N4c{TnWwY4Tpc44hSXO\|YYm=	M2faVlAvOSEQvF2=	NUTyR2NDPzJiaB?=	Ml:wSG1UVw>?	Mkjl[I9meyCwb4SgdoVi[3SrdnH0[UBO\UOyMjDteZRidnRiZYjwdoV{e2mxbh?=	M3OzXVIyQDRyN{G2
MDA-MB-231	M2KydmtqdmG\|ZTDBd5NigQ>?	NGHG[GwyOCEQvF2=	MYO1JI1qdg>?	M2HGc2ROW09?	Ml\i[I9meyCwb4SgbY5pcWKrdDDISGFEOmF?	NE\TcYkzOzR7M{S0PS=>
MDA-MB-231	MkTCT4lv[XOnIFHzd4F6	Ml:4NUDPxE1?	MXKyOEBp	M4PodGROW09?	MXfkc4V{KG6xdDDpcohq[mm2IFjERWM3KGG\|c3Xzd4VlKGG\|IHHj[ZR6dGG2aX;uJIxmfmWuczDv[kB1fWK3bHnu	MnLhNlM1QTN2NEm=
K562	MlXmT4lv[XOnIFHzd4F6				NGO2flRld2W\|IH7veEBqdmirYnn0JGhFSUN?	NHLLWGkzOzV7MUGxNS=>
Jurkat	M3rsZWN6fG:2b4jpZ{BCe3OjeR?=	MV[yNEDPxE1?	MoPJO\|IhcA>?	NHnZdnVFVVOR	M1\QUo5wKGO7dH;0c5hq[2m2eTDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvci=>	NHTsPIIzPDNyNEO0PC=>
HCT116	MXTBdI9xfG:\|aYOgRZN{[Xl?	NIfK[ZQ{KM7:TR?=	MWmyOEBp	MXHEUXNQ	NYLGSGxY\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDwOVMheHKxdHXpckBt\X[nbB?=	NHHlb5QzPDd4NkW2NC=>
KASUMI-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV63b2lmUUN3ME25PU4yPyCwTR?=	M1P5ZXNCVkeHUh?=
KARPAS-45	NYjhSoRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnjoTWM2OD1zN{OuPFkhdk1?	M4Sw[HNCVkeHUh?=
BHT-101	NFLkfJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rT[GlEPTB;MkS0MlE5KG6P	NEjHUWtUSU6JRWK=
H9	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYfJR\|UxRTJ3NT6wOEBvVQ>?	MUHTRW5ITVJ?
PA-1	Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\mTWM2OD1{OE[uNlYhdk1?	NH;ON5JUSU6JRWK=
NEC8	MkD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1WwN2lEPTB;Mki5MlM5KG6P	MVTTRW5ITVJ?
MHH-PREB-1	NWfGTYl2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLCTWM2OD1{OUSuOVMhdk1?	MoLnV2FPT0WU
NB7	NX;HVJJXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnvmTWM2OD1\|NEWuO\|Qhdk1?	M3y1OnNCVkeHUh?=
A3-KAW	M3HQ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRTRyMD61PUBvVQ>?	MUPTRW5ITVJ?
NB69	NILzc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEn3e4pKSzVyPUSxNU44OSCwTR?=	NEPmfoxUSU6JRWK=
EoL-1-cell	NXHmWJNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTR3NEK1JI5O	NH3uN\|JUSU6JRWK=
CHP-212	Ml7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLNTWM2OD12NUeuOVMhdk1?	MVrTRW5ITVJ?
C2BBe1	NYfOTldVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnH2TWM2OD12N{KuNVkhdk1?	M2\TeXNCVkeHUh?=
697	NH;u[YRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\ib2dYUUN3ME20O\|MvPDFibl2=	MV;TRW5ITVJ?
BCPAP	NUPOeZhTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTVyMT60NkBvVQ>?	MnG2V2FPT0WU
L-363	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIrrfodKSzVyPUWwN{4yKG6P	MXrTRW5ITVJ?
ES8	NHPvO2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rafGlEPTB;NUKzMlU{KG6P	MXPTRW5ITVJ?
BE-13	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rtSmlEPTB;NUK2Mlk3KG6P	MYrTRW5ITVJ?
CTB-1	NWrabGE6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEOxWHFKSzVyPUWzO{46OiCwTR?=	NFLifnRUSU6JRWK=
HD-MY-Z	NFLuW\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\IWmJKSzVyPUWzPE4yOyCwTR?=	NGTHS2VUSU6JRWK=
NKM-1	MkfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFTWO2ZKSzVyPUW0OE4zPyCwTR?=	M4fwWnNCVkeHUh?=
NCI-H720	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MljoTWM2OD13NkCuNVghdk1?	NEjrenRUSU6JRWK=
KY821	M4\BWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTV4Mz6yOUBvVQ>?	M2HacnNCVkeHUh?=
OVCAR-5	MlvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LuN2lEPTB;NUe2MlEyKG6P	NEjrXZlUSU6JRWK=
CTV-1	NUHrd4pPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTV6MT61OkBvVQ>?	NITRPFhUSU6JRWK=
P12-ICHIKAWA	NXHCfZV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlXtTWM2OD13OU[uOVEhdk1?	NF\k[lJUSU6JRWK=
DB	MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlPzTWM2OD13OUiuOVchdk1?	NY\MdI9{W0GQR1XS
CHL-1	NIXlPXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTZ2Mj6wPEBvVQ>?	MYrTRW5ITVJ?
A4-Fuk	NV[3WIRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DKPGlEPTB;NkS0MlkyKG6P	MYPTRW5ITVJ?
MV-4-11	MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYnpc4xCUUN3ME22OVkvOSCwTR?=	NHnofG5USU6JRWK=
RPMI-8226	NFTkNWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVPjOGdMUUN3ME22O\|gvOThibl2=	MWjTRW5ITVJ?
NB14	NX;ININET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXjiVVdXUUN3ME22PVYvQTVibl2=	M13nbXNCVkeHUh?=
DOHH-2	NXjLNoFET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnF[5VLUUN3ME23NFYvPjhibl2=	Mn\lV2FPT0WU
D-423MG	MoXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkjUTWM2OD15ME[uPFkhdk1?	MWrTRW5ITVJ?
D-283MED	M{H2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTdzND6xOEBvVQ>?	NGDl[21USU6JRWK=
ES1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPsNGZ2UUN3ME23NlQvPCCwTR?=	M3m4N3NCVkeHUh?=
GOTO	MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYjQfZBEUUN3ME23NlkvOTJibl2=	MkD4V2FPT0WU
NCI-H209	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3XTRWlEPTB;N{K5Mlkhdk1?	M3\JfHNCVkeHUh?=
MOLT-13	NIPs[GRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rVWWlEPTB;N{O4Mlk5KG6P	Mo\kV2FPT0WU
ATN-1	MoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHNUYtqUUN3ME23OFAvOjhibl2=	MUTTRW5ITVJ?
DU-4475	NIHoNm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTd3MT65NUBvVQ>?	M1SwenNCVkeHUh?=
NB10	NVHqN5pQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTd3MT65NkBvVQ>?	MYfTRW5ITVJ?
KG-1	NWrGbmpQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTd5NT60OUBvVQ>?	MVPTRW5ITVJ?
MOLT-4	NWTre4N3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\xUGlEPTB;N{i3MlQ3KG6P	MUXTRW5ITVJ?
TE-1	M4ewRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF6xc4JKSzVyPUe5NU4yKG6P	MoTTV2FPT0WU
SBC-1	M2fydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDoO4NKUUN3ME23PVMvQDRibl2=	Mn3aV2FPT0WU
HEL	MmP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4niVmlEPTB;OEC2MlA5KG6P	NUP0bYk2W0GQR1XS
SK-MEL-2	Mm\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\3TWM2OD16MEmuOFQhdk1?	MVjTRW5ITVJ?
KU812	M1XBSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRThzMz6xJI5O	NIGybGxUSU6JRWK=
RPMI-8866	MnHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LI[2lEPTB;OEGzMlY4KG6P	MX;TRW5ITVJ?
ALL-PO	NH;zOnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRThzND62OkBvVQ>?	MVPTRW5ITVJ?
LU-139	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrzTWM2OD16MkKuPFYhdk1?	NUj4NZBoW0GQR1XS
RS4-11	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTh\|Mj60OUBvVQ>?	M2S4bnNCVkeHUh?=
EW-18	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYfJR\|UxRTh\|Mj65OkBvVQ>?	NVnGd2t7W0GQR1XS
P30-OHK	MomwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmPRTWM2OD16M{WuO{BvVQ>?	M4P1VnNCVkeHUh?=
D-566MG	MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTh\|OD62NkBvVQ>?	NUG0dYZoW0GQR1XS
HSC-4	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTh2Nj61NUBvVQ>?	M1XnPHNCVkeHUh?=
QIMR-WIL	MkXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nZW2lEPTB;OE[yMlA{KG6P	MofNV2FPT0WU
SW954	NF30dmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\nTWM2OD16NkOuNVYhdk1?	MVLTRW5ITVJ?
HGC-27	NW[w[2lZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTh5Mj6zOEBvVQ>?	NUnuRnNZW0GQR1XS
HH	MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTh7ND6xNkBvVQ>?	MlzXV2FPT0WU
KE-37	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zsdGlEPTB;OEm0MlYzKG6P	MWjTRW5ITVJ?
SK-N-DZ	MkLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTlyMD60N{BvVQ>?	Ml;HV2FPT0WU
J-RT3-T3-5	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHTxdFJKSzVyPUmxNE41QSCwTR?=	NUfwW3F4W0GQR1XS
A427	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NISxb3VKSzVyPUmyNE45PCCwTR?=	MV\TRW5ITVJ?
ECC10	NHXVZVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVi2eFM3UUN3ME25OFUvQDdibl2=	NGDaTmNUSU6JRWK=
EW-1	M4roUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWCzcFdbUUN3ME25OFcvOjZibl2=	Mor4V2FPT0WU
MIA-PaCa-2	NGXYTFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1WwbGlEPTB;OUS5MlEzKG6P	NUPqNnA1W0GQR1XS
HCC2218	NVvNd\|VJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTl3OD60PEBvVQ>?	MVrTRW5ITVJ?
HAL-01	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\tTWM2OD17NkiuNFQhdk1?	NXrwOHpJW0GQR1XS
RD	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFvqUZdKSzVyPUm3OE41PSCwTR?=	NVnJOoo2W0GQR1XS
SK-N-AS	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17DSGlEPTB;OUi4MlEhdk1?	NEj4UJpUSU6JRWK=
ML-2	NWnY[JV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\sNmlEPTB;MT6wNFQxPyEQvF2=	NFnpNXRUSU6JRWK=
MEL-HO	NHTReFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLLTWM2OD1zLkCwOVgzKM7:TR?=	Mm\vV2FPT0WU
MS-1	NWDqVm9rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTFwMEC2NVch\|ryP	MkjIV2FPT0WU
NCI-SNU-1	NYW0dnlkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoH5TWM2OD1zLkCyN\|MyKM7:TR?=	NH\yVWVUSU6JRWK=
8505C	M4P5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1TMR2lEPTB;MT6wNlM{OSEQvF2=	MnzOV2FPT0WU
MN-60	Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mni2TWM2OD1zLkCyOlgh\|ryP	NVLDWmJ[W0GQR1XS
SAS	NXnhfno4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFL4U4dKSzVyPUGuNFQxQDFizszN	M1;ySHNCVkeHUh?=
EFM-19	NF;6XnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTFwMES4O\|kh\|ryP	MUnTRW5ITVJ?
Ca9-22	NVnrbIxoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmn3TWM2OD1zLkC1NVA4KM7:TR?=	MlvqV2FPT0WU
NBsusSR	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;KT2lEPTB;MT6wOVE3PiEQvF2=	MXHTRW5ITVJ?
NB13	Mn60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7vW\|JKSzVyPUGuNFU2ODFizszN	MX;TRW5ITVJ?
SF295	MmnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4KwbWlEPTB;MT6wOlYzPCEQvF2=	M1u0TnNCVkeHUh?=
U-2-OS	M2K2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkSwTWM2OD1zLkC3PVEyKM7:TR?=	NH\SbFVUSU6JRWK=
NCI-H526	NFjIPJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPnTG5KUUN3ME2xMlA5OjlzIN88US=>	NULRSJZ3W0GQR1XS
KMOE-2	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTFwMEm0NlIh\|ryP	NEPwbZpUSU6JRWK=
RCM-1	M1\COGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3TJTmlEPTB;MT6xNlExOiEQvF2=	MkLKV2FPT0WU
MC116	NYfEfGFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnP3TWM2OD1zLkGzOlIyKM7:TR?=	MojvV2FPT0WU
NCI-H1092	Ml:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGn0O3dKSzVyPUGuNVU1ODZizszN	Mm\iV2FPT0WU
EW-3	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGDJ[nJKSzVyPUGuNVczOTJizszN	M13kcHNCVkeHUh?=
HCT-116	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTFwMUe3OUDPxE1?	MYDTRW5ITVJ?
MC-IXC	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;vT3l2UUN3ME2xMlE4QDhzIN88US=>	MmXSV2FPT0WU
LB1047-RCC	Ml7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTFwMUizNVIh\|ryP	M{WyfnNCVkeHUh?=
VM-CUB-1	MlfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTFwMUmxNFgh\|ryP	MljOV2FPT0WU
NB5	M3:1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUXRcIJKUUN3ME2xMlE6QDV4IN88US=>	NVPUb2o6W0GQR1XS
SKG-IIIa	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjI[mhKSzVyPUGuNlM1PjRizszN	M3rldHNCVkeHUh?=
HO-1-N-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnfiTWM2OD1zLkKzPFM2KM7:TR?=	NHXuU29USU6JRWK=
EFO-27	M3G0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\CcpJKSzVyPUGuNlUxPDNizszN	NHjo[opUSU6JRWK=
MHH-NB-11	M1vmWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXiV494UUN3ME2xMlI5OzJ7IN88US=>	NWfFT4VsW0GQR1XS
SW620	MkjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rvWWlEPTB;MT6yPVAyQCEQvF2=	M4DRNXNCVkeHUh?=
MOLT-16	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXXDbYdMUUN3ME2xMlI6Pzl5IN88US=>	NUnDRpd[W0GQR1XS
NTERA-S-cl-D1	NEDIe29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTFwM{G3OlEh\|ryP	M4nncnNCVkeHUh?=
VA-ES-BJ	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTFwM{K0O\|ch\|ryP	MUnTRW5ITVJ?
HCC1419	MlXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHLTWM2OD1zLkO0NFI4KM7:TR?=	M1LyZXNCVkeHUh?=
NCI-H69	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrEO2pFUUN3ME2xMlM1OTF{IN88US=>	MUnTRW5ITVJ?
DEL	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnhTWM2OD1zLkO1NVYzKM7:TR?=	NUP5N3hUW0GQR1XS
LXF-289	M2TNS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTFwM{WyOEDPxE1?	NGLndYxUSU6JRWK=
EW-11	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4\Xe2lEPTB;MT6zOlAzPiEQvF2=	MV7TRW5ITVJ?
KP-4	MnjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXHoeZFoUUN3ME2xMlM4ODh3IN88US=>	NVTVVGpNW0GQR1XS
NOS-1	M3m5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXewV4UyUUN3ME2xMlQyOTl2IN88US=>	NUPhRlZJW0GQR1XS
SK-NEP-1	M2LxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGrB[FBKSzVyPUGuOFE3QTNizszN	MYLTRW5ITVJ?
LAMA-84	NVOxfmFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTFwNEO5OFUh\|ryP	NVnCVItHW0GQR1XS
ES5	NF32fmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUPyT\|R2UUN3ME2xMlQ1OyEQvF2=	NVTuSnhkW0GQR1XS
HuO9	NY\zWnhET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XyW2lEPTB;MT60OVM3OiEQvF2=	NXXoeI1jW0GQR1XS
COLO-684	MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVfMRotpUUN3ME2xMlQ3OTF6IN88US=>	NUnTdmVVW0GQR1XS
EW-24	M1nuZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1fWNGlEPTB;MT60OlU{OSEQvF2=	M4ru[nNCVkeHUh?=
BV-173	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTFwNEeyPVEh\|ryP	NIOwTI5USU6JRWK=
NCI-H1770	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;vZWxqUUN3ME2xMlQ5PTN4IN88US=>	M3nDbHNCVkeHUh?=
HuP-T4	M2\Wd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{jSTmlEPTB;MT60PVMh\|ryP	MlzsV2FPT0WU
TYK-nu	M2XJfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTFwNEm4OVEh\|ryP	M{j1V3NCVkeHUh?=
YH-13	M1W2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm[1TWM2OD1zLkS5PFk1KM7:TR?=	MkPsV2FPT0WU
H4	NGmzc3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTFwNUC5NVIh\|ryP	MmK1V2FPT0WU
OVCAR-8	M{LG[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1;xZ2lEPTB;MT61OFQ4PyEQvF2=	MkTuV2FPT0WU
NCI-H23	NWPHXY8yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkHSTWM2OD1zLkW0OlQ2KM7:TR?=	MoHDV2FPT0WU
ES7	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfEVWZSUUN3ME2xMlU1Pzd\|IN88US=>	NUDLdWNOW0GQR1XS
COR-L88	NIWxXIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYrq[\|JkUUN3ME2xMlU3PDJ2IN88US=>	MlvHV2FPT0WU
TI-73	NIPqSlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTFwNUmwOkDPxE1?	NUXYbmVtW0GQR1XS
RT-112	NHTiTHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXXDbpRCUUN3ME2xMlU6Ojh2IN88US=>	Mn\PV2FPT0WU
HuO-3N1	NI[5WlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HhfWlEPTB;MT61PVM5PSEQvF2=	M1PTcnNCVkeHUh?=
HC-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXJTWM2OD1zLkW5PFY3KM7:TR?=	MVfTRW5ITVJ?
HT55	MmTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorzTWM2OD1zLk[1NVMyKM7:TR?=	MXrTRW5ITVJ?
IA-LM	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4T2PWlEPTB;MT62PVI4QCEQvF2=	NVHUV\|FFW0GQR1XS
EM-2	NH3DOZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTFwN{CwNVQh\|ryP	NXv1UnFIW0GQR1XS
MHH-ES-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\0eGlEPTB;MT63NFQ{PSEQvF2=	MX\TRW5ITVJ?
CAL-27	NFzNPYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLlTWM2OD1zLkewOlIyKM7:TR?=	NV;pfGFpW0GQR1XS
COLO-800	M3vaO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\he\|NKSzVyPUGuO\|EyPzlizszN	NH7EdnNUSU6JRWK=
HCE-T	NVXjXZRwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fVRmlEPTB;MT63NVUh\|ryP	MUPTRW5ITVJ?
CAMA-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoTLTWM2OD1zLkexPVcyKM7:TR?=	MWnTRW5ITVJ?
LOXIMVI	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\PNGlEPTB;MT63NlEyKM7:TR?=	MVrTRW5ITVJ?
NH-12	Mn3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTFwN{K2PVEh\|ryP	M3TBUXNCVkeHUh?=
TCCSUP	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk[5TWM2OD1zLkeyPFI6KM7:TR?=	NGXl[Y9USU6JRWK=
MDA-MB-361	NFS0R\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2T6XmlEPTB;MT63N\|E2PyEQvF2=	NFfnR3pUSU6JRWK=
EW-16	NELyPYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYjZPGM3UUN3ME2xMlc1OTB5IN88US=>	NGPGXpVUSU6JRWK=
SNU-423	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\Wd2Z1UUN3ME2xMlc2QDJ5IN88US=>	MoPPV2FPT0WU
Daoy	Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEHrbWhKSzVyPUGuO\|Y{OTlizszN	NWPUSHdHW0GQR1XS
ES4	M{PteGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGH6[5RKSzVyPUGuO\|g4PDFizszN	Mn35V2FPT0WU
PFSK-1	M2Hic2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnL6TWM2OD1zLkiwN\|ch\|ryP	Ml7EV2FPT0WU
ES3	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIq2TYNKSzVyPUGuPFI3QDFizszN	NEDJfGtUSU6JRWK=
ONS-76	M3TaTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml:yTWM2OD1zLkiyPFk4KM7:TR?=	MnTYV2FPT0WU
JVM-3	NVPUSZJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTye5RrUUN3ME2xMlg2PDVzIN88US=>	NFO1WIhUSU6JRWK=
OS-RC-2	NEnHS5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HZSWlEPTB;MT64O\|E2OSEQvF2=	NH35UYxUSU6JRWK=
COLO-320-HSR	NWjtWJhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWPKO5lGUUN3ME2xMlg5OTl5IN88US=>	NIXqS3dUSU6JRWK=
HN	MlPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\ZNopKSzVyPUGuPFg4OjVizszN	MYjTRW5ITVJ?
HT	NUnqTW9tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4mwT2lEPTB;MT64PFk1PyEQvF2=	M{nkSnNCVkeHUh?=
LoVo	NHPobGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTFwOEm4NUDPxE1?	NYLBTWZFW0GQR1XS
CGTH-W-1	M1T1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3\oZ2lEPTB;MT64PVk1PiEQvF2=	NGL6[FlUSU6JRWK=
NB6	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTFwOUGyPVgh\|ryP	M1nGfXNCVkeHUh?=
EW-22	MnK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmfBTWM2OD1zLkmyPFg4KM7:TR?=	MknLV2FPT0WU
ES6	Mn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUPSfYFTUUN3ME2xMlk{PjNzIN88US=>	Mk\NV2FPT0WU
SCC-15	NGfRdXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTFwOUO4NVkh\|ryP	NH75eYlUSU6JRWK=
HL-60	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTFwOUO5NFIh\|ryP	NFnWWHBUSU6JRWK=
human HOP-92	M1XtPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTFwOUSwOlUh\|ryP	MmfwV2FPT0WU
SW626	MnjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\VPGhZUUN3ME2xMlk1QDl7IN88US=>	Mo\XV2FPT0WU
HEC-1	NUTNN5JjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfMdJV{UUN3ME2xMlk2OzZizszN	NU[4PVF6W0GQR1XS
LB2241-RCC	NGe4UoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTFwOUiyN\|Eh\|ryP	NWDVdFQzW0GQR1XS
Ramos-2G6-4C10	MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7KTW85UUN3ME2xMlk6PDl\|IN88US=>	NVzzT2JFW0GQR1XS
A101D	M33h[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoH3TWM2OD1{LkKwN\|A{KM7:TR?=	M2HlcXNCVkeHUh?=
NCI-H446	NXm3OVR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2PtRmlEPTB;Mj6wOFU6QSEQvF2=	NYXnSJpsW0GQR1XS
SBC-5	M3PjWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX61O2JIUUN3ME2yMlA3OTR5IN88US=>	NEPONHJUSU6JRWK=
HOS	MkHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHzTbXRKSzVyPUKuNFc3PTNizszN	MVzTRW5ITVJ?
K5	M4LwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlfLTWM2OD1{LkC3PFEyKM7:TR?=	NVzvOng2W0GQR1XS
HLE	MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rD[mlEPTB;Mj6wPFUzQSEQvF2=	NHvKZ5BUSU6JRWK=
HSC-2	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzKW4FtUUN3ME2yMlEzQDl6IN88US=>	NFXpNnFUSU6JRWK=
LCLC-97TM1	NITDfYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX7JR\|UxRTJwMUS1PFMh\|ryP	NFXMWmFUSU6JRWK=
DMS-273	M4ez[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVnaXlFwUUN3ME2yMlE1QDN5IN88US=>	NES5OFNUSU6JRWK=
TE-8	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTJwMUW3OlUh\|ryP	MonBV2FPT0WU
DSH1	M4S1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1fTXmlEPTB;Mj6xOlM6QCEQvF2=	M36yc3NCVkeHUh?=
CAL-51	NEe4cYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2j1fmlEPTB;Mj6xOlY6QSEQvF2=	MWPTRW5ITVJ?
IST-SL1	NGPLN4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXT1dphOUUN3ME2yMlE3QDR2IN88US=>	NWfHSpZbW0GQR1XS
GCT	Ml73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoC0TWM2OD1{LkG3O\|ch\|ryP	MXrTRW5ITVJ?
SW948	NIrqO\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTJwMUi0OVYh\|ryP	NFfpO3hUSU6JRWK=
NOMO-1	M1KxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIP1XodKSzVyPUKuNVk{OTdizszN	NH7VTIFUSU6JRWK=
C8166	Ml\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfMRWFKSzVyPUKuNlE{OzRizszN	MoP2V2FPT0WU
OC-314	NHTiXVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2LnR2lEPTB;Mj6yN\|I2QSEQvF2=	M1OyPHNCVkeHUh?=
CAL-39	MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rEUGlEPTB;Mj6yN\|YzPiEQvF2=	MnriV2FPT0WU
MDA-MB-453	M2XUSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTJwMkSyO\|Uh\|ryP	M1TzbnNCVkeHUh?=
A673	MmDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{ftNGlEPTB;Mj6yOVg3OiEQvF2=	NWiyVXp1W0GQR1XS
HTC-C3	NWHaSYY2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\IWmlEPTB;Mj6yOlg2KM7:TR?=	NGLGZVJUSU6JRWK=
NCI-H1666	NYnufmkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn7TTWM2OD1{LkK4NVEyKM7:TR?=	Moq3V2FPT0WU
PSN1	M335VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHpdpZKSzVyPUKuNlg6OTNizszN	MVzTRW5ITVJ?
GI-1	Mle4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXrFfFM1UUN3ME2yMlMxPTR\|IN88US=>	MXnTRW5ITVJ?
HuH-7	MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFntNW5KSzVyPUKuN\|A3OzdizszN	M{m2N3NCVkeHUh?=
JAR	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLjTWM2OD1{LkOxPVg4KM7:TR?=	MUPTRW5ITVJ?
5637	NYDySoR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\HbnBuUUN3ME2yMlMzOTJ7IN88US=>	M1XlTHNCVkeHUh?=
GB-1	M33qTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY\EU5JRUUN3ME2yMlMzOzN3IN88US=>	NIDmfphUSU6JRWK=
KP-N-YS	NFPjdZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHxXHlLUUN3ME2yMlMzPjF3IN88US=>	MnPZV2FPT0WU
OAW-42	NUPXc3BST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEe1dYZKSzVyPUKuN\|M1OTZizszN	M1\oVnNCVkeHUh?=
8-MG-BA	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEHjRoZKSzVyPUKuN\|M6ODZizszN	NWqzWGVQW0GQR1XS
RH-18	M{XKPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2HOS2lEPTB;Mj6zOVAzOiEQvF2=	NEjRSHlUSU6JRWK=
NCI-H1155	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHtTWM2OD1{LkO2O\|I2KM7:TR?=	MoTGV2FPT0WU
NB17	NH24SW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXi4[nNpUUN3ME2yMlM5OjR\|IN88US=>	NYjNVok{W0GQR1XS
NCI-H1437	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTJwNEG4O\|Mh\|ryP	NWH1NG5sW0GQR1XS
SN12C	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTJwNEOyNVQh\|ryP	M2rTOXNCVkeHUh?=
HSC-3	NGDJSVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTJwNES1NFkh\|ryP	NF7aOoRUSU6JRWK=
GAMG	M37kUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3X6NmlEPTB;Mj60OFU3OSEQvF2=	MnThV2FPT0WU
HT-1080	NGmzSmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXXoS21UUUN3ME2yMlQ1QDZ2IN88US=>	M4nRWnNCVkeHUh?=
A549	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWfnfJpDUUN3ME2yMlQ1QDl\|IN88US=>	NGnTVVBUSU6JRWK=
KNS-62	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXHjcWM3UUN3ME2yMlQ2ODZzIN88US=>	MUDTRW5ITVJ?
YKG-1	NUDD[ZZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTJwNEW0N\|ch\|ryP	MnrkV2FPT0WU
LU-134-A	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYixWVVKUUN3ME2yMlQ4ODB6IN88US=>	NEPJbHZUSU6JRWK=
FADU	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4DH[mlEPTB;Mj60O\|E3OiEQvF2=	MYLTRW5ITVJ?
TGBC11TKB	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYHubWtmUUN3ME2yMlQ4OTd5IN88US=>	M17nO3NCVkeHUh?=
HT-3	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFflOIVKSzVyPUKuOFk2OzVizszN	Mn\uV2FPT0WU
NCI-H2170	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLMTWM2OD1{LkWwOVQ6KM7:TR?=	MnTmV2FPT0WU
Mo-T	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTJwNUC5Nlch\|ryP	MmXGV2FPT0WU
CCRF-CEM	NUe3dIlNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWDjdY97UUN3ME2yMlU{ODR\|IN88US=>	M3nmXXNCVkeHUh?=
KU-19-19	M3v3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLqOo85UUN3ME2yMlU{PTF\|IN88US=>	M2n1UXNCVkeHUh?=
NCI-H1048	NYfHWGJIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoP0TWM2OD1{LkW1NFI2KM7:TR?=	NET1d21USU6JRWK=
KOSC-2	MnnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULOW2R4UUN3ME2yMlU3ODd4IN88US=>	NITsNHBUSU6JRWK=
A431	NI\xW25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHlTWM2OD1{LkW2N\|M2KM7:TR?=	M{i3bXNCVkeHUh?=
COR-L23	NEezdW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\mTWM2OD1{LkW4OVY3KM7:TR?=	MkjzV2FPT0WU
MKN28	M3LPcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1;hOWlEPTB;Mj61PVA{PyEQvF2=	M1zRe3NCVkeHUh?=
22RV1	NXnpR2h5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkfWTWM2OD1{LkW5Nlc1KM7:TR?=	NXq1Z2t[W0GQR1XS
ABC-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4jxc2lEPTB;Mj62NFQ3KM7:TR?=	MojaV2FPT0WU
NCI-H2126	Ml21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTJwNkC5PFQh\|ryP	M33pTHNCVkeHUh?=
DoTc2-4510	M4jvUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUP5e2FQUUN3ME2yMlYzOTh3IN88US=>	M4XFPHNCVkeHUh?=
SCC-4	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXJepNKSzVyPUKuOlMxOTJizszN	MV;TRW5ITVJ?
NCI-H661	NE\LUWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\4cpVKSzVyPUKuOlQxQDVizszN	M4D3b3NCVkeHUh?=
RPMI-2650	NHPadGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTJwNkSxOFMh\|ryP	NXu4e2ZuW0GQR1XS
NCI-H510A	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFzBcIlKSzVyPUKuOlQ1OjZizszN	MYLTRW5ITVJ?
BPH-1	NEXtN4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnhTWM2OD1{Lk[1PFUh\|ryP	MnzoV2FPT0WU
M14	Ml\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGLlXlRKSzVyPUKuOlY6QTNizszN	NIf0SG1USU6JRWK=
G-402	MlfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTJwN{C0OVEh\|ryP	NGG3Uo9USU6JRWK=
AsPC-1	Ml3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1frXGlEPTB;Mj63NVE4KM7:TR?=	MYPTRW5ITVJ?
NB12	M4j1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTJwN{G3NUDPxE1?	M3PhRnNCVkeHUh?=
SK-HEP-1	M174NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGfZUVRKSzVyPUKuO\|Q{QTFizszN	MXHTRW5ITVJ?
U-266	M1SwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1fwbmlEPTB;Mj63O\|EzOSEQvF2=	M1XhVXNCVkeHUh?=
AM-38	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY\1R4hLUUN3ME2yMlc4OzV3IN88US=>	M1n1T3NCVkeHUh?=
PC-14	M2e5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYPod2MyUUN3ME2yMlgxPTFizszN	M{fwT3NCVkeHUh?=
EGI-1	M3ridWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTJwOEG3OFMh\|ryP	MmrTV2FPT0WU
LS-411N	NE[3cI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTJwOEKzN{DPxE1?	MY\TRW5ITVJ?
BFTC-905	NHSwUGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHHjZZBKSzVyPUKuPFU2OjNizszN	M{f1Z3NCVkeHUh?=
CaR-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\TdYlIUUN3ME2yMlg3KM7:TR?=	MnnhV2FPT0WU
NCI-H292	Ml3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWnmcYpmUUN3ME2yMlg3PTl4IN88US=>	MlvvV2FPT0WU
8305C	M1zKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDPdXJGUUN3ME2yMlg3PjR3IN88US=>	MX\TRW5ITVJ?
SNU-449	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTJwOEmxPFIh\|ryP	NVnLcWxxW0GQR1XS
LCLC-103H	MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHO1XmJKSzVyPUKuPVA1OzhizszN	NIHue\|NUSU6JRWK=
SW1573	M3jsd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzoXGFoUUN3ME2yMlk3ODh{IN88US=>	NXjMWm5rW0GQR1XS
MLMA	NFrOeGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHlWXJ4UUN3ME2yMlk3PzF5IN88US=>	NGHsN\|dUSU6JRWK=
NCI-H1355	NGXCNmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFzUWWZKSzVyPUOuNFA4QTZizszN	MlfjV2FPT0WU
RMG-I	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXvR[IE1UUN3ME2zMlAzPTl{IN88US=>	Mn7rV2FPT0WU
BB65-RCC	NVvJ[JZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX;vZ4RJUUN3ME2zMlA{OzF2IN88US=>	NUjucGlFW0GQR1XS
PC-3	M4PGZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\PUWlEPTB;Mz6wN\|g4PCEQvF2=	NYLGeWVtW0GQR1XS
SF268	MkfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mlf6TWM2OD1\|LkC0OVI{KM7:TR?=	NWr1bo97W0GQR1XS
NCI-H810	M3;zOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTNwMES4NlMh\|ryP	MX7TRW5ITVJ?
MEG-01	MkL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmjhTWM2OD1\|LkC2NVY1KM7:TR?=	NFXjNGZUSU6JRWK=
SW13	MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYXsNHZ1UUN3ME2zMlA4QDR5IN88US=>	NGDLbHlUSU6JRWK=
RH-1	M3nkTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXz0e4toUUN3ME2zMlExOjd6IN88US=>	M4XCeXNCVkeHUh?=
GT3TKB	NYnoTIxKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGfD[JBKSzVyPUOuNVEzQDNizszN	MWPTRW5ITVJ?
TK10	NI\WdZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTNwMUO3NlQh\|ryP	MXnTRW5ITVJ?
T-24	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnkT3ZKSzVyPUOuNVUxPyEQvF2=	MojhV2FPT0WU
A498	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2TIUGlEPTB;Mz6yNFg4OSEQvF2=	NVXGfIh5W0GQR1XS
GR-ST	MmjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXLGcJBHUUN3ME2zMlIzOTN7IN88US=>	M4\ONHNCVkeHUh?=
LB2518-MEL	M3X4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{[4TmlEPTB;Mz6yNlM6QCEQvF2=	M3j1cHNCVkeHUh?=
T47D	MoHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTNwMkO2Nlch\|ryP	M4HSXHNCVkeHUh?=
NCI-H1651	MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTNwMkS2OFQh\|ryP	NIO2ZolUSU6JRWK=
EC-GI-10	Mlf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvWeYJKSzVyPUOuNlYyPTNizszN	NFq2W4RUSU6JRWK=
HT-29	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHtTWM2OD1\|LkK2OlE1KM7:TR?=	MofqV2FPT0WU
GI-ME-N	M{mwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRTNwMkm1NVEh\|ryP	MXrTRW5ITVJ?
SW756	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoX0TWM2OD1\|LkK5OlI6KM7:TR?=	NULKcYduW0GQR1XS
RKO	M2H3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYOwbHhkUUN3ME2zMlMxPzV5IN88US=>	NFWzdldUSU6JRWK=
NCI-H1563	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\XTWM2OD1\|LkOzNFE5KM7:TR?=	NI\LWpdUSU6JRWK=
DJM-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFvVPG5KSzVyPUOuN\|c3PzRizszN	NUTtWlE3W0GQR1XS
L-428	MmDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHlTWM2OD1\|LkSwNFQ2KM7:TR?=	NYTEWoJQW0GQR1XS
NCI-H2122	NXHuboo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTNwNEGzNVIh\|ryP	M1PkV3NCVkeHUh?=
Ca-Ski	Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTNwNEW0N{DPxE1?	M2jyS3NCVkeHUh?=
639-V	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{LqV2lEPTB;Mz60OlA2PyEQvF2=	MYfTRW5ITVJ?
SW1116	M3TzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4r6XGlEPTB;Mz60OlI3QSEQvF2=	MX\TRW5ITVJ?
DMS-114	NF3jOZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTNwNEewOlYh\|ryP	M2rlRXNCVkeHUh?=
MZ2-MEL	NVLsfWpZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2TzRmlEPTB;Mz60O\|Y5OSEQvF2=	M3G2PHNCVkeHUh?=
COLO-829	MnHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFK5NZVKSzVyPUOuOVAxPzNizszN	NXrxbZk5W0GQR1XS
J82	NH3vd\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7vTWM2OD1\|LkWwOVch\|ryP	NX[2WFl{W0GQR1XS
EW-13	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTNwNUK1NUDPxE1?	MUTTRW5ITVJ?
RXF393	M2mzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnW1TWM2OD1\|LkWzNlk1KM7:TR?=	NWfmVlZwW0GQR1XS
CAL-62	NHXi[mxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjBToltUUN3ME2zMlU1PTF2IN88US=>	M3;PSHNCVkeHUh?=
OCUB-M	NXrOUFN{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTNwNUS2OlUh\|ryP	M13hbHNCVkeHUh?=
BT-474	M1nzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHL[lBKSzVyPUOuOlM{OSEQvF2=	Ml7aV2FPT0WU
KYSE-180	MljsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfxSXZKSzVyPUOuOlM{PzJizszN	NYTQb4t7W0GQR1XS
NCI-H650	NGfKflJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\s[VlKSzVyPUOuOlQzQDdizszN	M3TtVnNCVkeHUh?=
Detroit562	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk\HTWM2OD1\|Lk[1NFIzKM7:TR?=	NUH6OHlVW0GQR1XS
SW48	MmfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTNwNkW2OVch\|ryP	Mnm3V2FPT0WU
KYSE-450	M3\KcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rkVGlEPTB;Mz62PFU5OiEQvF2=	NELCb2ZUSU6JRWK=
KYSE-510	M3T1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTNwN{KxPFEh\|ryP	MWrTRW5ITVJ?
GP5d	M3TENGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4naNmlEPTB;Mz63Nlk2KM7:TR?=	M{XhT3NCVkeHUh?=
RPMI-7951	Ml;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{[0VWlEPTB;Mz63OFczOyEQvF2=	MVvTRW5ITVJ?
Becker	NF;WZ2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGDuNppKSzVyPUOuO\|UxOTJizszN	MXXTRW5ITVJ?
WM-115	MknPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTNwN{ixPVUh\|ryP	MmLTV2FPT0WU
G-401	NW\ZRlJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYH0fFRJUUN3ME2zMlc6ODh3IN88US=>	M3zETnNCVkeHUh?=
PANC-08-13	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnZWZUzUUN3ME2zMlc6PjB{IN88US=>	NHLrZ\|dUSU6JRWK=
SW982	MofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXr1dpF2UUN3ME2zMlgxPTVzIN88US=>	NUDSWpozW0GQR1XS
D-263MG	NWXnPIxuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TvRWlEPTB;Mz64NlA2OSEQvF2=	NYfjclhxW0GQR1XS
KM-H2	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2nVSGlEPTB;Mz64NlYzPCEQvF2=	MUTTRW5ITVJ?
SK-MEL-3	NVnh[HBvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmL4TWM2OD1\|LkiyPFQyKM7:TR?=	MYfTRW5ITVJ?
NCI-H1581	NETmfVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jRd2lEPTB;Mz64OFQ5QCEQvF2=	M1v1enNCVkeHUh?=
LS-123	MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTNwOEe5NFkh\|ryP	MkXlV2FPT0WU
CAKI-1	MkDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXr[5VSUUN3ME2zMlg6ODV{IN88US=>	NHrDU4lUSU6JRWK=
MEL-JUSO	NHfWNXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDB[\|RKSzVyPUOuPFkyPTNizszN	Mm\uV2FPT0WU
HCE-4	M1rwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTNwOUG2OlMh\|ryP	MWTTRW5ITVJ?
TE-10	MkOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmG0TWM2OD1\|LkmyNFEh\|ryP	MVjTRW5ITVJ?
OVCAR-4	NFT5cVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULkN3dLUUN3ME2zMlkzQDh7IN88US=>	MVHTRW5ITVJ?
ETK-1	NV\qPY9rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoKxTWM2OD1\|Lkm0OlM2KM7:TR?=	NGW0boxUSU6JRWK=
A2780	NFXtRmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLyTWM2OD12LkC1PVY3KM7:TR?=	M3vaZXNCVkeHUh?=
LU-65	MljpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\aTWM2OD12LkC3OlM{KM7:TR?=	MkLLV2FPT0WU
BHY	M3zCPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYnuTphVUUN3ME20MlEzPDl3IN88US=>	NFnadnhUSU6JRWK=
COR-L105	M1fnO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjXfJNKSzVyPUSuNVMxPTFizszN	NGLvd5hUSU6JRWK=
CAL-12T	NYS0NIpIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIj2[lJKSzVyPUSuNVMyODNizszN	Mof3V2FPT0WU
SCH	NFz3d\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnCeGtjUUN3ME20MlE2PzR\|IN88US=>	M33pcHNCVkeHUh?=
CW-2	MnjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LidmlEPTB;ND6xPVAxOSEQvF2=	NVexZWd[W0GQR1XS
HCC1806	MkDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGLEOnFKSzVyPUSuNlA{OTJizszN	NWDPUoVoW0GQR1XS
KP-N-YN	NFLaRWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3z4eGlEPTB;ND6yNFkzPyEQvF2=	NVW3dI9VW0GQR1XS
T98G	M2rz[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLpPI9KSzVyPUSuNlIyPTdizszN	MXvTRW5ITVJ?
CAL-54	M{K0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTRwMkKzPFEh\|ryP	NFv2WXBUSU6JRWK=
CAL-33	M3:xTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnUSHlKSzVyPUSuNlMxPjRizszN	MYfTRW5ITVJ?
SNU-C2B	MlvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHzFZ5pKSzVyPUSuNlQ4PjlizszN	M1;DWXNCVkeHUh?=
NUGC-3	M{n3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33GdmlEPTB;ND6yOVUxPSEQvF2=	NG\xRZBUSU6JRWK=
DOK	M4LFS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mni5TWM2OD12LkK2OVk{KM7:TR?=	NX3vVVc4W0GQR1XS
MMAC-SF	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFm1R5NKSzVyPUSuNlY5PTlizszN	M3nURnNCVkeHUh?=
KYSE-70	M1;GW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LUUWlEPTB;ND6yPVM1KM7:TR?=	NHnqXo9USU6JRWK=
A204	NYfKR4t7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYjUSnBRUUN3ME20MlM2QDB\|IN88US=>	M2XxOHNCVkeHUh?=
SCC-25	NWH0UG05T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfvSm1KSzVyPUSuN\|U5OTlizszN	NEDIVYRUSU6JRWK=
EPLC-272H	NV;vW3p{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mkj5TWM2OD12LkO4PVUh\|ryP	M{[3SnNCVkeHUh?=
CAL-120	NWTpWZVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{nqOmlEPTB;ND6zPFk6OiEQvF2=	M2LnT3NCVkeHUh?=
LS-513	MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY\1dJd3UUN3ME20MlQzOTl6IN88US=>	NH[0[VNUSU6JRWK=
CAPAN-1	NFvhWZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEexZW5KSzVyPUSuOFI{QDJizszN	M3jGXXNCVkeHUh?=
ESS-1	MnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULnTZk2UUN3ME20MlQzPzJ2IN88US=>	NFXvc2xUSU6JRWK=
GMS-10	NFTnc5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFnOPFBKSzVyPUSuOFI5OTlizszN	M4n0WHNCVkeHUh?=
NCI-N87	M3Lk[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3iwTmlEPTB;ND61NFg3QCEQvF2=	NFflcYhUSU6JRWK=
HMV-II	MoT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jnPWlEPTB;ND61NVc{KM7:TR?=	MWnTRW5ITVJ?
COLO-741	M2faU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnPETWM2OD12LkW1PVk1KM7:TR?=	MVLTRW5ITVJ?
MKN45	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTBPXFYUUN3ME20MlU4PzN{IN88US=>	NELoZVdUSU6JRWK=
OAW-28	NFfWc\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHSyfnVKSzVyPUSuOVg{QThizszN	M17lVXNCVkeHUh?=
OCI-AML2	MlTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXOfpkxUUN3ME20MlY2OjN6IN88US=>	MVPTRW5ITVJ?
MDA-MB-231	M3Ppemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mkm0TWM2OD12LkewNlQ{KM7:TR?=	M373b3NCVkeHUh?=
NCI-H1648	NHjhR\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWXFS3FJUUN3ME20MlczOjd\|IN88US=>	MnXaV2FPT0WU
NCI-H1792	NELa[WpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTRwN{[xNFch\|ryP	M3fQTnNCVkeHUh?=
GCIY	NXTZOJBsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XSPGlEPTB;ND63O\|QzPCEQvF2=	NVm5[mRpW0GQR1XS
Hs-578-T	NXm5ZYJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEO1WJRKSzVyPUSuO\|c3PTVizszN	MlzzV2FPT0WU
SW962	NF;tV\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGfLeY1KSzVyPUSuO\|gxOTFizszN	NX3OO4liW0GQR1XS
NCI-H630	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zh[2lEPTB;ND63PFA5OSEQvF2=	NFXadWZUSU6JRWK=
786-0	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVj4PGZCUUN3ME20Mlc5Pzd\|IN88US=>	MnznV2FPT0WU
FTC-133	NUXUR4FzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzmcXNvUUN3ME20Mlc6OjZ\|IN88US=>	NVTpV443W0GQR1XS
BT-20	Mn\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTRwN{m0Nlkh\|ryP	M33sNHNCVkeHUh?=
Mewo	M4Xqdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4j3eGlEPTB;ND64NVc1PyEQvF2=	M4KzW3NCVkeHUh?=
SW780	M2nzXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVvCVWlJUUN3ME20Mlg2PzZ4IN88US=>	MoP6V2FPT0WU
OE33	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2Xtc2lEPTB;ND64O\|cyOyEQvF2=	NFjJT3pUSU6JRWK=
HCC1569	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWD0W4xCUUN3ME20Mlg5PDV6IN88US=>	NV\aV3Q3W0GQR1XS
TE-6	M1;QbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkfwTWM2OD12LkmzPVc4KM7:TR?=	M{LuN3NCVkeHUh?=
SK-N-FI	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3TzNWlEPTB;ND65OFQzOSEQvF2=	MWLTRW5ITVJ?
PANC-03-27	M3H1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIjlbWdKSzVyPUSuPVk6PjJizszN	M2\t[HNCVkeHUh?=
MCF7	M3m0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXCTopKSzVyPUWuNFA4OzhizszN	M{K3ZXNCVkeHUh?=
UACC-257	MmTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFv2V5pKSzVyPUWuNFI5PDVizszN	MVTTRW5ITVJ?
SW1088	M3S0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3HrUmlEPTB;NT6wNlk1PCEQvF2=	NF7IPG1USU6JRWK=
A704	Mn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTVwMEOwOkDPxE1?	MYnTRW5ITVJ?
A2058	Mlu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4Dl[mlEPTB;NT6wOVkxQCEQvF2=	M4CyUnNCVkeHUh?=
Calu-3	NECzXGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\WRWlEPTB;NT6wOlQ2OiEQvF2=	M2r4S3NCVkeHUh?=
RERF-LC-MS	NF;4XplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTVwME[5NFMh\|ryP	MnTxV2FPT0WU
AU565	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoS3TWM2OD13LkC5O\|AzKM7:TR?=	MmrGV2FPT0WU
DMS-79	MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkDaTWM2OD13LkGzPFg{KM7:TR?=	NEfje3VUSU6JRWK=
DK-MG	NXXUUHlmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTVwMUi0N\|gh\|ryP	MV\TRW5ITVJ?
HuCCT1	Mo\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG[2cmNKSzVyPUWuNlM5PTZizszN	NEjFUIRUSU6JRWK=
HT-144	M{D2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTVwMkS5PFch\|ryP	MlvtV2FPT0WU
M059J	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjvblNKSzVyPUWuNlU4PiEQvF2=	M{PkUnNCVkeHUh?=
COLO-792	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\0TWM2OD13LkK2N\|U3KM7:TR?=	NXnm[ms{W0GQR1XS
SF539	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPmTWM2OD13LkK2OlMzKM7:TR?=	M3vkVHNCVkeHUh?=
SK-UT-1	NYjZNmM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3SzXWlEPTB;NT6yO\|c2OSEQvF2=	M37s[nNCVkeHUh?=
NCI-H1703	NVTQV2FET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\Fc2lEPTB;NT6zOVgzPiEQvF2=	Mki3V2FPT0WU
SW837	MnnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDUTWM2OD13LkO3PFc5KM7:TR?=	M{n6S3NCVkeHUh?=
U251	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLpW3VKSzVyPUWuN\|kxQTZizszN	M{HrOXNCVkeHUh?=
SW1710	NIL3SI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlm3TWM2OD13LkSxOVU1KM7:TR?=	NFzFdVJUSU6JRWK=
NCI-H1299	NUnUcVFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrGXI5mUUN3ME21MlQ3OzN3IN88US=>	MVzTRW5ITVJ?
RVH-421	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV3FSlFZUUN3ME21MlQ6QTB6IN88US=>	MUnTRW5ITVJ?
UM-UC-3	NVTwdlVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUiyNpM2UUN3ME21MlYzPjVzIN88US=>	MYLTRW5ITVJ?
MDA-MB-175-VII	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHzsfHdKSzVyPUWuOlQxPDFizszN	MWXTRW5ITVJ?
KYSE-270	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fXVWlEPTB;NT62OlA{OSEQvF2=	MXXTRW5ITVJ?
COLO-668	M1TxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHT6dXRKSzVyPUWuO\|E{OiEQvF2=	NIW5cGNUSU6JRWK=
LN-405	M4npUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrMfGsyUUN3ME21Mlc{ODh3IN88US=>	MWPTRW5ITVJ?
HT-1376	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml3ZTWM2OD13Lke4NFUzKM7:TR?=	MYPTRW5ITVJ?
769-P	M4L0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTVwOE[3NVgh\|ryP	NGDnWYdUSU6JRWK=
HuP-T3	NV6zWXVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTVwOEi2O\|ch\|ryP	MX;TRW5ITVJ?
MDA-MB-415	NVX2WG52T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PpS2lEPTB;NT65NlE{QSEQvF2=	Mk\6V2FPT0WU
MKN7	NUXwT4RlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\PTWM2OD13Lkm4PEDPxE1?	MkOzV2FPT0WU
KS-1	MnnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NET1[WxKSzVyPUWuPVg5OzZizszN	NXy2PVhRW0GQR1XS
647-V	NVThclNKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTVwOUmxOFgh\|ryP	MU\TRW5ITVJ?
COLO-679	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIf3UJRKSzVyPU[uNFAzPTVizszN	M{ezVXNCVkeHUh?=
AN3-CA	MoXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2racmlEPTB;Nj6wN\|Q1OSEQvF2=	MXTTRW5ITVJ?
C32	MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTZwMUOwN\|Qh\|ryP	NYTzb2dyW0GQR1XS
KM12	M4fuR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlLBTWM2OD14LkK0NFk6KM7:TR?=	MUjTRW5ITVJ?
KINGS-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml32TWM2OD14LkK2NVUzKM7:TR?=	MmfjV2FPT0WU
KYSE-410	M4LQemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\jb2lEPTB;Nj6zNFY1PSEQvF2=	NFnlc2JUSU6JRWK=
HPAF-II	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTZwM{W0PEDPxE1?	NWnQ[\|F3W0GQR1XS
LAN-6	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXJW3hoUUN3ME22MlQ6PjNzIN88US=>	MlG3V2FPT0WU
LU-99A	M3P4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTWTWM2OD14LkW1PVg6KM7:TR?=	NXTDU4xKW0GQR1XS
SJSA-1	NUjmbI1XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFP6TWpKSzVyPU[uOVY{PDdizszN	MVHTRW5ITVJ?
MSTO-211H	MoXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmnJTWM2OD14LkeyNlM{KM7:TR?=	NI\nOmNUSU6JRWK=
SW900	NGHpVYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPSXJpKSzVyPU[uO\|YzOjFizszN	MVLTRW5ITVJ?
LNCaP-Clone-FGC	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NITYSoZKSzVyPU[uPFA1ODNizszN	NXLvN3lyW0GQR1XS
OMC-1	NVfXSm5oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXfIcWxVUUN3ME22Mlg2PDB{IN88US=>	NHW1N3NUSU6JRWK=
IST-MEL1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTZwOEm2Olkh\|ryP	NYrTVldEW0GQR1XS
TE-9	M2jjfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLJUYg3UUN3ME22Mlg6QDR5IN88US=>	NFHiNFdUSU6JRWK=
NCI-H2030	NX:3fIVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTZwOUGyNlYh\|ryP	Mn\IV2FPT0WU
BFTC-909	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1ewZ2lEPTB;Nz6wNFY1OSEQvF2=	MVHTRW5ITVJ?
NCI-SNU-5	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFy3WJZKSzVyPUeuNFIyPTlizszN	MX\TRW5ITVJ?
TE-5	M3XCdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4WwVGlEPTB;Nz6wNlg5OSEQvF2=	M2frfXNCVkeHUh?=
SK-MES-1	NUTpN5ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmPxTWM2OD15LkC1OFI4KM7:TR?=	NGHhR3NUSU6JRWK=
SHP-77	MnfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2PvWGlEPTB;Nz6xN\|k2OiEQvF2=	NXvVVoJnW0GQR1XS
NCI-H1623	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Moj1TWM2OD15LkG0NFczKM7:TR?=	NGLSe4VUSU6JRWK=
TE-11	NVLVOWFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTdwMUWxPFQh\|ryP	MVLTRW5ITVJ?
EKVX	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnj6TWM2OD15LkG5NlY4KM7:TR?=	M{K2ZXNCVkeHUh?=
OVCAR-3	M1:0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnj3TWM2OD15LkKxNVM{KM7:TR?=	NXrk[Wx7W0GQR1XS
C3A	NH7VeGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2G2[GlEPTB;Nz6zOFUzKM7:TR?=	M2fGUXNCVkeHUh?=
CFPAC-1	NHTnVoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTdwM{[yNlIh\|ryP	NYHMR3ZrW0GQR1XS
MG-63	MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTucZJKSzVyPUeuOFE5PDlizszN	MnjvV2FPT0WU
KYSE-140	NHG2WmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGf4epRKSzVyPUeuOFQxPjFizszN	NH7tWHpUSU6JRWK=
MPP-89	MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33D[2lEPTB;Nz61PVczQSEQvF2=	NFP4VoNUSU6JRWK=
COLO-824	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYTYPYlCUUN3ME23MlczQDZ\|IN88US=>	MlfHV2FPT0WU
SiHa	MkfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlG4TWM2OD15LkizO\|A4KM7:TR?=	MWPTRW5ITVJ?
SNU-387	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnTnTWM2OD15Lki1N\|Q4KM7:TR?=	M{G4RnNCVkeHUh?=
A172	NWrETYl1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1rHc2lEPTB;Nz64OlE4OiEQvF2=	NVXCSnp4W0GQR1XS
COLO-680N	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XSSWlEPTB;Nz65NVc{KM7:TR?=	MYXTRW5ITVJ?
HCC1395	NVLOfXRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mly0TWM2OD16LkC1OFUzKM7:TR?=	MmrzV2FPT0WU
NCI-H28	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXztPYpDUUN3ME24MlA2QTZ\|IN88US=>	NF30UItUSU6JRWK=
LC-2-ad	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1XqfWlEPTB;OD6yNVk{PyEQvF2=	NYXpeVhmW0GQR1XS
S-117	NGLibpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1fZWWlEPTB;OD6yOVM2OyEQvF2=	NGruZWFUSU6JRWK=
NCI-H1838	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGDBc3NKSzVyPUiuNlU4QDFizszN	MkXJV2FPT0WU
PANC-10-05	MljQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRThwM{ewOFch\|ryP	NIfhZoRUSU6JRWK=
KALS-1	MoTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHmTWM2OD16LkWwPVI5KM7:TR?=	MV3TRW5ITVJ?
LS-1034	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRThwNUe0N\|ch\|ryP	MmSyV2FPT0WU
TGBC1TKB	NUL2XGllT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDVZ4tKSzVyPUiuO\|M2OzVizszN	M4nROHNCVkeHUh?=
OE19	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEC2bXRKSzVyPUiuO\|YzPjJizszN	M1fwVnNCVkeHUh?=
D-502MG	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;QRplDUUN3ME24Mlc3QTl2IN88US=>	Mny0V2FPT0WU
JEG-3	Mk\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PZU2lEPTB;OD63PFYyQCEQvF2=	NXjnfI5YW0GQR1XS
DBTRG-05MG	M1;HcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnheGtKSzVyPUiuPFc2PjVizszN	NUXMZWk2W0GQR1XS
ME-180	M3Gzd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTlwME[3NlUh\|ryP	MmfrV2FPT0WU
NCI-H1573	NV7BR5dWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTlwMUC1N\|Ih\|ryP	Mn;BV2FPT0WU
HCC2998	M{PRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\nTWM2OD17LkGzOlgyKM7:TR?=	Mn3TV2FPT0WU
ACHN	NWLRRoR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3HWOmlEPTB;OT6yOFk4PSEQvF2=	NFTIXHJUSU6JRWK=
D-392MG	NEnwW4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3fvbmlEPTB;OT6yOVcyPSEQvF2=	M4SwS3NCVkeHUh?=
no-11	NWnmbJpTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV:zSXl2UUN3ME25MlI3ODJ6IN88US=>	MoTzV2FPT0WU
KLE	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHJTWM2OD17LkOyNlMzKM7:TR?=	M2HRbXNCVkeHUh?=
Calu-6	MnvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTlwM{e1Nlgh\|ryP	M{m4TXNCVkeHUh?=
LB831-BLC	MlrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1rDUWlEPTB;OT60OVE4OSEQvF2=	MkeyV2FPT0WU
SW684	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH6zO\|VKSzVyPUmuOFYyOTZizszN	NGriXY1USU6JRWK=
SH-4	NGOyblhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFq0UIVKSzVyPUmuOFk{PjRizszN	M2KxUHNCVkeHUh?=
IST-MES1	NEe5O3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTlwNUG2OFQh\|ryP	MYfTRW5ITVJ?
Saos-2	NEW1SZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7KTWM2OD17LkWyNVk2KM7:TR?=	NHjIcIdUSU6JRWK=
NCI-H2087	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkjOTWM2OD17Lk[3N\|UzKM7:TR?=	MUDTRW5ITVJ?
SCC-9	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTlwN{G4NVYh\|ryP	MU\TRW5ITVJ?
MFE-280	M4nPTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUKzVHRSUUN3ME25MlczPzh3IN88US=>	NVuwe3F1W0GQR1XS
BEN	NFO3TW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV35TYx4UUN3ME25MlgzOTV7IN88US=>	M3HRcHNCVkeHUh?=
CP50-MEL-B	NWPHdI5MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVi4RVkyUUN3ME25MlkzPDN{IN88US=>	M33INnNCVkeHUh?=
SK-MEL-28	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTFyLkCxPVMh\|ryP	Mlm4V2FPT0WU
NCI-H2452	NWLzZZRxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTFyLkG2JO69VQ>?	NGDu[4hUSU6JRWK=
NCI-H1395	NXK3[3dVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDBTWM2OD1zMD6xO\|gh\|ryP	M{e5bnNCVkeHUh?=
NCI-H2052	NYPPdY1vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXRTWM2OD1zMD6xPFgzKM7:TR?=	Mnr6V2FPT0WU
A375	NGX3SpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTQTWM2OD1zMD6yOFUzKM7:TR?=	NHnXOldUSU6JRWK=
HCC38	NV7lPYVKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTmZlBKSzVyPUGwMlMzOiEQvF2=	NWLB[m5SW0GQR1XS
LK-2	M1WybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PPV2lEPTB;MUCuOFIxQCEQvF2=	NGDGO4FUSU6JRWK=
SF126	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvZTWM2OD1zMD60O\|I4KM7:TR?=	M2PsPHNCVkeHUh?=
SK-MEL-1	MkLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFnuTJBKSzVyPUGwMlc5OzhizszN	NYTKRnpyW0GQR1XS
ACN	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{fwNGlEPTB;MUCuPFY4QSEQvF2=	MXXTRW5ITVJ?
BB30-HNC	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHzaT2JKSzVyPUGwMlg4OTFizszN	MmO4V2FPT0WU
NCI-H747	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTFyLki3OFYh\|ryP	NEnjdoVUSU6JRWK=
KYSE-150	NUe2doRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Moj2TWM2OD1zMT6wN\|g4KM7:TR?=	NXfWXJl2W0GQR1XS
D-247MG	M1\2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTFzLkGwNFkh\|ryP	NGXROXBUSU6JRWK=
BxPC-3	NVy2T5c{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7mTWM2OD1zMT6zO\|Q4KM7:TR?=	NFfxcnNUSU6JRWK=
SK-MEL-30	MlHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTFzLkSwO\|kh\|ryP	NXTPRXpQW0GQR1XS
CAS-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1HwcGlEPTB;MUGuOFExQSEQvF2=	NFrKdYhUSU6JRWK=
no-10	M3fPc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTF{LkGyNVch\|ryP	MVzTRW5ITVJ?
NCI-H2405	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEC3d3FKSzVyPUGyMlIxOzZizszN	MoeyV2FPT0WU
KGN	MoXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NInnWpJKSzVyPUGyMlI6ODFizszN	MYTTRW5ITVJ?
BB49-HNC	M{j5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILCOYdKSzVyPUGyMlM6PTZizszN	NHnJW\|JUSU6JRWK=
NCI-H1693	MnLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIPKNG9KSzVyPUGyMlU5OTZizszN	Mk\FV2FPT0WU
RO82-W-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX[0bHFuUUN3ME2xN{4xPjR7IN88US=>	NFvmSpNUSU6JRWK=
CAL-85-1	NUjwUmU5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\6PGlEPTB;MUOuOFM6QSEQvF2=	NHzVOY9USU6JRWK=
H-EMC-SS	NYrFT4RWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;2R2lEPTB;MUOuPVExPCEQvF2=	M3;W[3NCVkeHUh?=
SW1783	NEj2WYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGnUVmZKSzVyPUG0MlI{QTFizszN	NED1ZWhUSU6JRWK=
LB771-HNC	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3XxPGlEPTB;MUSuOFE6KM7:TR?=	NF;V[HdUSU6JRWK=
HCC70	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LoNWlEPTB;MUSuOFI{OyEQvF2=	NUfwZldbW0GQR1XS
KNS-81-FD	M3\SVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|UxRTF2LkewOFUh\|ryP	M2rmeXNCVkeHUh?=
KYSE-520	NHLuVJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fwU2lEPTB;MUSuPVI4KM7:TR?=	NFG3b\|VUSU6JRWK=
TGBC24TKB	NFflRm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF[4W5FKSzVyPUG0Mlk2OzlizszN	MX7TRW5ITVJ?
SNB75	NWXIbVZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVzHZlRCUUN3ME2xOU4xPzJ7IN88US=>	MmfHV2FPT0WU
SW872	MlnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXzoTlhRUUN3ME2xOU4zOjF6IN88US=>	NVK0XWJDW0GQR1XS
U031	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTF3LkiwNlgh\|ryP	M4fBXHNCVkeHUh?=
ChaGo-K-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk\4TWM2OD1zNT64N\|U6KM7:TR?=	MlPhV2FPT0WU
NCI-H441	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NETUfGdKSzVyPUG2MlAxOzlizszN	MorkV2FPT0WU
TE-12	NYq3b2RyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn;LTWM2OD1zNj6xPFc{KM7:TR?=	M33HPHNCVkeHUh?=
NCI-H1755	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXpRXNKSzVyPUG2MlU4OyEQvF2=	M1jVc3NCVkeHUh?=
KNS-42	NIm4UWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{LJ[GlEPTB;MU[uOlU5QSEQvF2=	M{Pi[nNCVkeHUh?=
SK-PN-DW	MnfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrGZmF5UUN3ME2xO{41OjBzIN88US=>	NGHuflhUSU6JRWK=
NCI-H226	Mme2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLjTWM2OD1zNz65N\|Q2KM7:TR?=	M3e3d3NCVkeHUh?=
K-562	M3XRTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjrNIVKSzVyPUG4MlY{OTdizszN	M1nlTHNCVkeHUh?=
A388	M1fwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3kbIZvUUN3ME2xPU4xOzB\|IN88US=>	NWDnT\|hJW0GQR1XS
ZR-75-30	NVeyUlZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPRRmI3UUN3ME2xPU4xQTZ6IN88US=>	MkPEV2FPT0WU
LU-135	MlzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3zpTmlEPTB;MUmuNlY{PiEQvF2=	NHL1cXhUSU6JRWK=
NCI-H2029	M4rSN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnSyTWM2OD1zOT62NFIyKM7:TR?=	MlHPV2FPT0WU
HT-1197	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoTqTWM2OD1zOT65NlI4KM7:TR?=	NHrKV5ZUSU6JRWK=
IGR-1	NGX4NGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTJyLkOxNVch\|ryP	Mne5V2FPT0WU
U-87-MG	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTJyLk[0NVMh\|ryP	MXzTRW5ITVJ?
NCI-H1304	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHu4bGhKSzVyPUKwMlc2ODFizszN	M2PV[nNCVkeHUh?=
RCC10RGB	MkTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vE[mlEPTB;MkGuNlgzQSEQvF2=	MlzOV2FPT0WU
NCI-H520	NW\qe41pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\tZmlEPTB;MkKuO\|YyOSEQvF2=	NH3FZYRUSU6JRWK=
SK-LU-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml3HTWM2OD1{Mz6wO\|E5KM7:TR?=	MlzwV2FPT0WU
UACC-893	MlHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1TJPGlEPTB;MkOuNVA{QCEQvF2=	MnvXV2FPT0WU
NCI-H2347	M3jRdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXn0WJV4UUN3ME2yN{4zPjd2IN88US=>	NEnESmlUSU6JRWK=
U-118-MG	NFfBc3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfOTZFKSzVyPUKzMlczOTdizszN	NU[1NpRsW0GQR1XS
NCI-H596	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkXrTWM2OD1{Mz65NFU2KM7:TR?=	MVXTRW5ITVJ?
MZ1-PC	NX3W[G9bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTJ2Lk[3OVkh\|ryP	NHHQT5VUSU6JRWK=
SW1417	NYGzWml5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTJ3LkK0PVgh\|ryP	MV3TRW5ITVJ?
NCI-H82	MmfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTJ4LkSyPFgh\|ryP	MYfTRW5ITVJ?
COLO-678	NHTLS3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTJ5LkS5NVkh\|ryP	MoHkV2FPT0WU
KURAMOCHI	M3Hsb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnS4TWM2OD1{OD6xNlYh\|ryP	NIr2XYpUSU6JRWK=
NCI-H1650	NFLQfJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkXuTWM2OD1\|MD6xPVI1KM7:TR?=	NF;lcHdUSU6JRWK=
HCC1954	Mof2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTNzLkO2OlYh\|ryP	MlXTV2FPT0WU
GAK	NIr1ZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnGfG5VUUN3ME2zNk4zPjF4IN88US=>	MnrtV2FPT0WU
YAPC	M3rTU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTN\|Lke2OFgh\|ryP	NGruT2pUSU6JRWK=
NCI-H2228	NUTQOnh2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTN2LkO2NFUh\|ryP	Mm\1V2FPT0WU
VMRC-RCZ	M{DYe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEDkbJRKSzVyPUO2MlMxOjJizszN	NFX0S4tUSU6JRWK=
NMC-G1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrZUotKSzVyPUO3MlA2OjlizszN	NVPifZdoW0GQR1XS
D-336MG	M1rSVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjCTWM2OD12MT64OFQzKM7:TR?=	MmK3V2FPT0WU
UACC-62	NFeyZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTR{LkW1NFUh\|ryP	M{T6THNCVkeHUh?=
C-33-A	NXrJNHpOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHvTHFHUUN3ME20OU4{OjV4IN88US=>	M2\yTHNCVkeHUh?=
HCC1937	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYrwPIZ4UUN3ME20O{4yQTV6IN88US=>	NVHPbnJGW0GQR1XS
HDLM-2	M{TIVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWLRfFM4UUN3ME20O{4zOjh5IN88US=>	M1:0e3NCVkeHUh?=
NCI-H727	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTR5LkK0OVEh\|ryP	MnjsV2FPT0WU
NY	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTR7LkO5NFgh\|ryP	MWnTRW5ITVJ?
NCI-H2291	NVLTOWk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DYWmlEPTB;NEmuPFMxOSEQvF2=	NYPOT\|dNW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Ac-Histone H4 / Ac-Histone H3; PubMed: 21598070 J Neurooncol D54 and U87 glioma cells were treated with lower concentrations (1-3 µM) of vorinostat. The effects on histone acetylation was assessed by immunoblotting. phospho-CDK1; PubMed: 21598070 Changes in level of inhibitory phosphorylation of cdk1 after treatment with vorinostat was determined at 24 and 48 h (using a Tyr-15 residue phospho-specific antibody) along with total cdk1 as loading control. phospho-Cdc25c / Cdc25c; PubMed: 21598070 J Neurooncol Time course of changes in phospho-cdc25c levels after exposure to vorinostat (5 µM). Cyclin B1; PubMed: 21598070 J Neurooncol Cyclin B1 levels were determined in D54 and U87 cells after treatment with various doses of vorinostat at 24 and 48 h. c-Myc / c-Raf / Akt / Cyclin D1 / CDK4; PubMed: 19440035 Cancer Biol Ther Cell lysates from JeKo-1 and Mo2058 cells exposed to vorinostat were immunoblotted for c-Myc, c-Raf, AKT, cyclin D1, CDK4 and acetylated histone H3. The levels of β-actin served as the loading control. p-eIF2α / ATF4 / CHOP ; PubMed: 20072656 Neoplasia Western blot was performed to evaluate activated eIF2α (P-eIF2α), translational up-regulation of ATF4, and CHOP expression in U251 cells after vorinostat exposure. p21; PubMed: 21598070 J Neurooncol To determine the dose response relationship to vorinostat, cells were exposed to various higher concentrations (5–10 µM) of the agent and the levels of p21 determined by immunoblotting.	21598070 19440035 20072656
Immunofluorescence	HDAC1 / CK19; PubMed: 29917299 Cancer Sci Immunocytochemistry to detect the expression of HDAC1 and CK 19 in PDAC cells with/without Vorinostat treatment. HDAC1 and CK19 were stained red and green, respectively. The Hoechst‐stained nuclei appear blue. Scale bar: 100 μm. The CK19 expression in PSN1 and MiaPaCa2 was increased by Vorinostat treatment. Nrf2; PubMed: 20566897 Blood Vorinostat induced translocation of Nrf2 from cytosol to nucleus. U937 cells were treated with 2μM vorinostat for 18 hours and then cytospun. Cells were fixed and labeled for Nrf2 protein (red) and nucleus (blue, 4,6-diamidino-2-phenylindole) as described in “Immunofluorescence and confocal microscopy.” Images were taken by Nikon Eclipse TE2000 confocal microscope with 40×/1.30 numeric aperture oil objective lens. Ctrl indicates control cells without treatment; and Vor, vorinostat. α-SMA; PubMed: 26330748 Mol Vis Representative immunofluorescence images and the quantification graph showing the effect of vorinostat (2.5 µM), TGIF1, and TGIF2 siRNA knockdown on αSMA. Control human corneal fibroblast cultures (-TGFβ) showed no αSMA staining. Cultures treated with TGFβ1 (5 ng/ml) showed a robust αSMA staining. Vorinostat treatment markedly attenuated TGFβ-evoked αSMA staining. The knockdown of TGIF1 (+TGFβ+vorinostat+TGIF1siRNA) and TGIF2 alone (+TGFβ+vorinostat+TGIF2siRNA) or in combination (+TGFβ +vorinostat +TGIF1 +2siRNA) markedly blocked the effect of vorinostat on αSMA. Scale bar=100 μm. Ac-STAT3 / IGF2; PubMed: 27086926 Oncogene Immunofluorescence staining of Ac-STAT3 and IGF2 after vorinostat treatment.	29917299 20566897 26330748 27086926
Growth inhibition assay	Cell apoptosis; PubMed: 19440035 Cancer Biol Ther Cells were treated with indicated concentrations of vorinostat for 48 hours. Following this, the percentage of annexin-V-stained apoptotic cells was determined by flow cytometry. Values represented as bar graphs are the mean of 3 experiments plus or minus the standard error (SE) Cell viability; PubMed: 27086926 Oncogene The effects of vorinostat on the viability of the indicated NSCLC cell lines and their corresponding acquired VoR sublines. Cell viability was determined by the MTT assay (n = 3).	19440035 27086926
ELISA	IGF2; PubMed: 27086926 Oncogene Determination of vorinostat-induced IGF2 production by ELISA (n = 3). The conditioned mediums (CMs) obtained from cells treated with vorinostat (5 μM) for 2 days were used for ELISA. IL-13 / IL-10 / IL-5; PubMed: 18541724 Blood Effect of vorinostat on TH1/TH2 cytokine secretion in HL cell lines. Cells were incubated with medium or vorinostat (5 μM) for 24 hours and supernatants were examined for cytokine levels by ELISA. Each value represents a mean of 3 independent experiments done in triplicate (± SEM). M-CSF; PubMed: 23042302 Carcinogenesis Primary PyMT tumor cells were treated with SAHA (0-1000nM) for varying time points (8–48h), and supernatants were assayed by ELISA for M-CSF secretion. P < 0.05 and P < 0.001 versus control treatment. MMP-9; PubMed: 23042302 Carcinogenesis Primary PyMT tumor cells were treated with SAHA (0-1000nM) for varying time points (8–48h), and supernatants were assayed by ELISA for MMP-9 secretion. P < 0.05 and **P < 0.001 versus control treatment.	27086926 18541724 23042302

In vivo

Administration of Vorinostat (~100 mg/kg/day) significantly inhibits the growth of CWR22 human prostate xenografts in nude mice with tumor reductions of 78%, 97% and 97%, at doses of 25 mg/kg/day, 50 mg/kg/day and 100 mg/kg/day, respectively, compared with control. Vorinostat induces the accumulation of acetylated core histones and prostate-specific antigen mRNA expression in CWR22 cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. ^[2] Oral administration of Vorinostat (0.67g/L) crosses the blood-brain barrier, increases histone acetylation in the brain, and dramatically improves the motor impairment in the R6/2 mice model of Huntington's disease. ^[5]

Protocol

Kinase Assay: ^[1]	+ Expand Immunoprecipitation-HDAC assays: The lysate of Jurkat cells is incubated for 1 hour on ice and cleared by centrifugation at 12,000 g for 10 minutes at 4 °C. Supernatants are precleared with 30 μL of 50% protein G-Sepharose slurry for 1 hour at 4 °C. Beads are pelleted by centrifugation and supernatants are incubated for 1 hour at 4 °C with 10 μg of IgG fraction from anti-HDAC1 or HDAC3 polyclonal antisera (preincubated 2 hours at room temperature with either the homologous or heterologous immunizing peptide). Both antisera are raised in rabbits against the carboxylterminal peptide of HDAC1 and HDAC3 by using synthetic peptides coupled to keyhole limpet hemocyanin. 30 μL of 50% protein G-Sepharose slurry is added for 1 hour at 4 °C. Immune complexes are pelleted by centrifugation and washed three times with 1 mL of lysis buffer. Beads are resuspended in 200 μL of HDAC buffer (20 mM Tris-HCl, pH 8.0/150 mM NaCl/10% glycerol), and the HDAC assay is performed with an ³H-acetylated peptide corresponding to amino acids 1-24 of histone H4. Released [³H]acetic acid is quantified by scintillation counting. For inhibitions studies, the immunoprecipitated complexes are preincubated with the different concentrations of Vorinostat for 30 minutes at 4 °C.
Cell Research: ^[2]	+ Expand Cell lines: LNCaP, PC-3, and TSU-Pr1 Concentrations: Dissolved in DMSO, final concentrations ~7.5 μM Incubation Time: 1, 2, 3 and 4 days Method: Cells are exposed to various concentrations of Vorinostat for 1, 2, 3 and 4 days. Cell viability is assessed by trypan blue dye exclusion. (Only for Reference)
Animal Research: ^[2]	+ Expand Animal Models: Male BALB/c nude (nu/nu) mice implanted with CWR22 tumor cells Formulation: Dissolved in DMSO Dosages: ~100 mg/kg/day Administration: Injection i.p. (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	52 mg/mL (196.74 mM)
	Ethanol	3 mg/mL (11.35 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Vorinostat (SAHA, MK0683) SDF

Molecular Weight	264.3
Formula	C₁₄H₂₀N₂O₃
CAS No.	149647-78-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	SAHA, MK0683, suberoylanilide hydroxamic acid

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03022565	Suspended	Drug: Vorinostat	Uveal Melanoma	University of Miami\|University of Miami Sylvester Comprehensive Cancer Center	January 2020	Early Phase 1
NCT03167437	Recruiting	Drug: Vorinostat	Crohn''s Disease	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	October 30 2017	Phase 1\|Phase 2
NCT03056495	Recruiting	Drug: N-hydroxy-N''-phenyl-octanediamide (Vorinostat)	Alzheimer Disease	German Center for Neurodegenerative Diseases (DZNE)\|University Hospital Bonn\|University of Göttingen	September 28 2017	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommendation about reconstitution of the compound for in vivo animal study?
Answer:
We recommend the following vehicle for S1047: 2% DMSO, 40% PEG 300, 5% Propylene glycol, 1% Tween 80 at 5 mg/mL.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Entinostat (MS-275)

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Vorinostat (SAHA, MK0683)

Cited by 182 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Vorinostat (SAHA, MK0683) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Choose Your Country or Region

By Signaling Pathways

By product type

Vorinostat (SAHA, MK0683)

Cited by 182 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Vorinostat (SAHA, MK0683) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)